

THE UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF ILLINOIS

)  
THE PEOPLE OF THE STATE OF ILLINOIS, )  
THE PEOPLE OF JERSEY COUNTY, and )  
COUNTY of JERSEY )  
)  
Plaintiffs, )  
)  
v. ) CIVIL ACTION NO. 3:17-cv-856  
)  
AMERISOURCEBERGEN DRUG )  
CORPORATION; )  
)  
CARDINAL HEALTH, INC.; CARDINAL )  
HEALTH 112, LLC; CARDINAL HEALTH )  
110, LLC ; CARDINAL HEALTH 108, LLC; )  
CARDINAL HEALTH 105, INC.; CARDINAL )  
HEALTH 414, LLC; and )  
)  
McKESSON CORPORATION, )  
)  
)  
Defendants. ) **COMPLAINT**  
 ) Complaint for Public Nuisance;  
 ) Violations of Racketeer Influenced and  
 ) Corrupt Organizations Act, 18 U.S.C. §§  
 ) 1961 *et seq.*; Illinois Narcotics Profit  
 ) Forfeiture Act, 725 ILCS 175/1 *et seq.*;  
 ) Illinois Consumer Fraud and Deceptive  
 ) Business Practices Act, 815 ILCS 505/1 *et  
seq.*; Uniform Deceptive Trade Practices  
 ) Act, 815 ILCS 510/1 *et seq.*; and  
 ) Negligence  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
 )  
**JURY TRIAL DEMANDED AND**  
**ENDORSED HEREON**  
 )  
 )

NOW COME Plaintiffs, THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, and undersigned Special Assistant State's attorneys, and bring this action against Defendants, Amerisourcebergen Drug Corporation, Cardinal Health, Inc., Cardinal Health 112, LLC, Cardinal Health 110, LLC, Cardinal Health 108, LLC, Cardinal Health 105, Inc., Cardinal Health 414, LLC, and McKesson Corporation (collectively, "Defendants"), for public nuisance; for violations of the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. §§ 1961 *et seq.*, Illinois Narcotics Profit Forfeiture Act, 725 ILCS 175/1 *et seq.*, Illinois Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 505/1 *et seq.*, and Uniform Deceptive Trade Practices Act, 815 ILCS 510/1 *et seq.*; and for negligence. Plaintiffs allege that certain DEA registered distributors **unlawfully** sold millions of prescription opioids into Jersey County, Illinois. *See Masters Pharm., Inc. v. Drug Enf't Admin.*, 861 F.3d 206 (D.C. Cir. 2017). Plaintiffs assert that such unlawful conduct resulted in the **foreseeable**, widespread diversion of prescription opioids into the illicit market, 1970 U.S.C.C.A.N. §§ 4566, 4571-72, creating a serious public health and safety crisis in Jersey County involving opioid abuse, addiction, morbidity and mortality, and is a public nuisance.

Plaintiffs allege as follows:

## **I. STANDING**

1. The State's Attorney is empowered to bring this action, and the Counts in this action, on behalf of Plaintiffs pursuant to the powers and duties vested to him by 55 ILCS 5/3-9005 and the doctrine of *parens patriae*. *See also* 55 ILCS 5/1-6003.
2. Plaintiffs, THE PEOPLE OF JERSEY COUNTY and COUNTY OF JERSEY, by BENJAMIN L. GOETTEEN, the State's Attorney of County of Jersey, have standing to bring this

public nuisance action for damages and to abate the public nuisance in Jersey County. 55 ILCS 5/5-1001; 55 ILCS 5/3-9005; 55 ILCS 5/1-6003.

3. Plaintiffs, THE PEOPLE OF JERSEY COUNTY and COUNTY OF JERSEY, have standing to bring claims under the federal RICO statute. 18 U.S.C. § 1961(3) (“persons” include counties); 18 U.S.C. § 1964 (“persons” have standing).

4. Plaintiffs, THE PEOPLE OF JERSEY COUNTY and COUNTY OF JERSEY, have standing to bring claims for civil relief under the Narcotics Profit Forfeiture Act. 725 ILCS 175/3(c) (“Person” includes any individual or entity capable of holding a legal or beneficial interest in property.”); 725 ILCS 175/6(c) (person injured has standing).

5. BENJAMIN L. GOETTEN, the State’s Attorney of Jersey County, believes this action to be in the public interest of the Plaintiffs, THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY. The State’s Attorney brings Count IV of this action pursuant to Section 7 of the Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 505/7(a).

6. The Plaintiffs, THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, are “government[s] or governmental subdivision[s]” and are therefore “person[s]” with standing to bring Count V under the Uniform Deceptive Trade Practices Act, 815 ILCS 510/1(5).

7. Plaintiffs, THE PEOPLE OF JERSEY COUNTY and COUNTY OF JERSEY, by BENJAMIN L. GOETEEN, the State’s Attorney of County of Jersey, have standing to bring Count VI, a common law action for negligence. 55 ILCS 5/5-1001; 55 ILCS 5/3-9005; 55 ILCS 5/1-6003.

## **II. PARTIES**

### **A. Plaintiffs.**

8. Plaintiffs, THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, are authorized to enforce the causes of action brought herein. The County is a body politic and corporate, organized and existing under the laws of the State of Illinois, which may sue in any court having subject-matter jurisdiction. 55 ILCS 5/5-1001.

9. The County Board of Jersey County, Illinois, has declared, *inter alia*, that opioid<sup>1</sup> abuse, addiction, morbidity and mortality has created a serious public health and safety crisis in Jersey County, Illinois, and is a public nuisance, and that the diversion of legally produced controlled substances into the illicit market causes or contributes to this public nuisance. Exhibit 1.

### **B. Defendants.**

10. Defendant, AMERISOURCEBERGEN DRUG CORPORATION, is registered with the Illinois Secretary of State as a Delaware corporation which may be served through its registered agent for service of process, CT Corporation System, 208 So. LaSalle Street, Suite 814, Chicago, Illinois 60604. AMERISOURCEBERGEN DRUG CORPORATION's principal place of business is located in Chesterbrook, Pennsylvania. AMERISOURCEBERGEN DRUG CORPORATION is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation, and operates distribution centers in Illinois, including in Romeoville, Illinois.

---

<sup>1</sup> As used herein, the term "opioid" refers to the entire family of opiate drugs including natural, synthetic and semi-synthetic opiates.

11. Defendant, CARDINAL HEALTH, INC. is an Ohio corporation, with its principal office located in Dublin, Ohio. Under the name "Cardinal Health," Defendant is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation.

12. CARDINAL HEALTH 112, LLC, is a subsidiary of CARDINAL HEALTH, INC., is registered with the Illinois Secretary of State as having its principal office in Ohio, is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation, and may be served through its registered agent for service of process, CT Corporation System, 208 So. LaSalle Street, Suite 814, Chicago, Illinois 60604.

13. CARDINAL HEALTH 110, LLC, is a subsidiary of CARDINAL HEALTH, INC., is registered with the Illinois Secretary of State as having its principal office in Ohio, is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation, and may be served through its registered agent for service of process, CT Corporation System, 208 So. LaSalle Street, Suite 814, Chicago, Illinois 60604.

14. CARDINAL HEALTH 108, LLC, is a subsidiary of CARDINAL HEALTH, INC., is registered with the Illinois Secretary of State as having its principal office in Tennessee, is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation, and may be served through its registered agent for service of process, CT Corporation System, 208 So. LaSalle Street, Suite 814, Chicago, Illinois 60604.

15. CARDINAL HEALTH 105, INC., is a subsidiary of CARDINAL HEALTH, INC., is registered with the Illinois Secretary of State as an Ohio Corporation having its principal office in Ohio, is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation, and may be served through its registered agent for service of process, CT Corporation System, 208 So. LaSalle Street, Suite 814, Chicago, Illinois 60604.

16. CARDINAL HEALTH 414, LLC, is a subsidiary of CARDINAL HEALTH, INC., is registered with the Illinois Secretary of State as having its principal office in Ohio, is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation, and may be served through its registered agent for service of process, CT Corporation System, 208 So. LaSalle Street, Suite 814, Chicago, Illinois 60604.

17. CARDINAL HEALTH, INC., CARDINAL HEALTH 112, LLC, CARDINAL HEALTH 110, LLC, CARDINAL HEALTH 108, LLC, CARDINAL HEALTH 105, INC., and/or CARDINAL HEALTH 414, LLC (occ. collectively “Cardinal Health”) operate distribution centers in Illinois, including in Aurora, Illinois. Cardinal Health also operates distribution centers outside of Illinois from which Cardinal Health ships opioids into Illinois, including in Jersey County.

18. Defendant, McKESSON CORPORATION, is registered with the Illinois Secretary of State as a Delaware corporation which may be served through its registered agent for service of process, Illinois Corporation Service Company, 801 Adlai Stevenson Drive, Springfield, Illinois 62703. McKESSON CORPORATION has its principal place of business located in San Francisco, California. McKesson is licensed as a wholesale drug distributor by the Illinois Department of Financial and Professional Regulation, and operates distribution centers in Illinois, including in Aurora, Illinois.

19. Defendants, collectively referred to herein sometimes as “Defendant Wholesale Distributors” or “Defendants,” are in the chain of distribution of prescription opioids, namely hydrocodone and oxycodone. Illinois is in the midst of a public health crisis stemming from the flood of opioids pouring into, *inter alia*, Jersey County.

20. In 1970, Congress devised a “closed” chain of distribution specifically designed to prevent the diversion of legally produced controlled substances into the illicit market. *Gonzales v. Raich*, 545 U.S. 1, 12–14 (2005); 21 U.S.C. § 801(2); 21 U.S.C. §§ 821-824, 827, 880; H.R. Rep. No. 91-1444, 1970 U.S.C.C.A.N. 4566, 4572 (Sept. 10, 1970). This closed-system imposes specific duties upon wholesale distributors to monitor, identify, halt and report “suspicious orders” of controlled substances. 21 C.F.R. § 1301.74; *Masters Pharm., Inc. v. Drug Enft Admin.*, 861 F.3d 206 (D.C. Cir. 2017).

21. As discussed *infra*, it has become abundantly clear that the Defendant Wholesale Distributors universally failed to comply with federal law. Plaintiffs allege the unlawful conduct by the Defendant Wholesale Distributors is responsible for the *volume* of prescription opioids plaguing our community.

22. However, the data which reveals the identity of each wrongdoer is hidden from public view in the DEA’s confidential ARCOS database. *Madel v. USDOJ*, 784 F.3d 448 (8th Cir. 2015). Neither the DEA<sup>2</sup> nor the Defendant Wholesale Distributors<sup>3</sup> will voluntarily disclose the data necessary to identify with specificity the transactions which will form the evidentiary basis for the claims asserted herein.

---

<sup>2</sup> See Declaration of Katherine L. Myrick, Chief, Freedom of Information (FOI)/Privacy Act Unit (“SARF”), FOI, Records Management Section (“SAR”), Drug Enforcement Administration (DEA), United States Department of Justice (DOJ), *Madel v. USDOJ*, Case 0:13-cv-02832-PAM-FLN, (Document 23) (filed 02/06/14), attached hereto as Exhibit 2 (noting that ARCOS data is “kept confidential by the DEA”).

<sup>3</sup> See Declaration of Tina Lantz, Cardinal Health VP of Sales Operation, *Madel v. USDOJ*, Case 0:13-cv-02832-PAM-FLN, (Document 93) (filed 11/02/16), attached hereto as Exhibit 3 (“Cardinal Health does not customarily release any of the information identified by the DEA notice letter to the public, nor is the information publicly available. Cardinal Health relies on DEA to protect its confidential business information reported to the Agency.”).

23. Consequently, Plaintiffs have named *inter alia* three (3) wholesale distributors (i.e., Amerisourcebergen Drug Corporation, Cardinal Health, Inc., and McKesson Corporation) which dominate 85% of the market share for the distribution of prescription opioids. The “Big 3” are Fortune 500 corporations listed on the New York Stock Exchange whose principal business is the nationwide wholesale distribution of prescription drugs. *See Fed. Trade Comm'n v. Cardinal Health, Inc.*, 12 F. Supp. 2d 34, 37 (D.D.C. 1998) (describing Cardinal Health, Inc., McKesson Corporation, and Amerisourcebergen Drug Corporation predecessors). Each has been investigated and/or fined by the DEA for the failure to report suspicious orders. Plaintiffs have reason to believe each has engaged in unlawful conduct which resulted in the diversion of prescription opioids into our community and that discovery will likely reveal others who likewise engaged in unlawful conduct. Plaintiffs name each of the “Big 3” herein as defendants and place the industry on notice that the citizens of Jersey County are taking action to abate the public nuisance plaguing our community. Plaintiffs, to more fully identify the volume of the prescription opioids unlawfully sold into our community, will request expedited discovery pursuant to Rule 26(d) of the Federal Rules of Civil Procedure to secure the data, including the ARCos data.

### **III. JURISDICTION AND VENUE**

24. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1331 because Plaintiffs’ claims hinging on 21 U.S.C. § 823 and 21 C.F.R. 1301.74 necessarily raise a federal issue which is actually disputed, substantial, and capable of resolution in federal court without disrupting the federal-state balance approved by Congress. *See Gunn v. Minton*, 568 U.S. 251 (2013). This Court further has subject matter jurisdiction pursuant 28 U.S.C. § 1331 because Plaintiffs’ RICO claims also raise a federal question. This Court has supplemental jurisdiction over Plaintiffs’ state law claims pursuant to 28 U.S.C. § 1337 because those claims are so related to Plaintiffs’ federal claims that they form part of the same case or controversy.

25. This Court has personal jurisdiction over Defendants because they conduct business in Illinois, purposefully direct and/or directed their actions toward Illinois, consented to be sued in Illinois by registering an agent for service of process, consensually submitted to the jurisdiction of Illinois when obtaining an Illinois wholesale distributor license, and have the requisite minimum contacts with Illinois necessary to constitutionally permit the Court to exercise jurisdiction.

26. Venue is proper in the Southern District of Illinois pursuant to 28 U.S.C. § 1391 and 18 U.S.C. §1965 because a substantial part of the events or omissions giving rise to the claim occurred in this District and each Defendant transacted affairs and conducted activity that gave rise to the claim of relief in this District. 28 U.S.C. § 1391(b); 18 U.S.C. §1965(a).

#### **IV. FACTUAL BACKGROUND**

27. Opioid analgesics hydrocodone and oxycodone are widely diverted and improperly used, and the widespread use of these drugs has resulted in a national epidemic of opioid overdose deaths and addictions.<sup>4</sup> The epidemic is “directly related to the increasingly widespread misuse of powerful opioid pain medications.”<sup>5</sup>

28. Defendant Wholesale Distributors owe a *duty* under both federal law (21 U.S.C. § 823, 21 C.F.R. 1301.74) and Illinois law (*e.g.*, 225 ILCS 120/40; Ill. Admin. Code Title 68, § 1510.50(i)), to monitor, detect, investigate, refuse to fill, and report suspicious orders of prescription opioids originating from Jersey County, Illinois as well as those orders which Defendants knew or should have known were likely to be diverted into Jersey County.

---

<sup>4</sup> See Nora D. Volkow, M.D. and A. Thomas McLellan, Ph.D., *Opioid Abuse in Chronic Pain – Misconceptions and Mitigation Strategies*, NEW ENG. J. MED., 374;1253-63 (March 31, 2016).

<sup>5</sup> Special Report, FDA Commissioner Robert M. Califf, M.D., *A Proactive Response to Prescription Opioid Abuse*, NEW ENGL. J. MED., 374;1480-85 (April 14, 2016).

29. The *foreseeable* harm from a breach of this duty is the diversion of prescription opioids for nonmedical purposes.

30. Each Defendant Wholesale Distributor repeatedly and purposefully *breached* its duties under state and federal law, which is a direct and proximate *cause* of the widespread diversion of prescription opioids for nonmedical purposes into Jersey County, Illinois.

31. The unlawful diversion of prescription opioids is a direct and proximate *cause* of the opioid epidemic, prescription opioid abuse, addiction, morbidity and mortality in the State of Illinois and Jersey County. This diversion and the epidemic are direct causes of harms incurred by the County itself.

32. The opioid epidemic in Illinois, including *inter alia* in Jersey County, remains an immediate *hazard to public health and safety*.

33. The opioid epidemic in Jersey County, is a temporary and continuous *public nuisance* and remains unabated.

34. Plaintiffs bring this civil action against the Defendant Wholesale Distributors seeking *inter alia damages* necessary to recoup the costs incurred by the County as a result of the nuisance, *damages* necessary to eliminate the hazard to public health and safety as well as *abatement* of the public nuisance, including both injunctive relief, an abatement fund, and a monetary award.

35. Plaintiffs further bring this action to recover *inter alia damages* incurred as a result of Defendants' RICO enterprise, Defendants' violations of the Illinois Narcotics Profit Forfeiture Act, the Illinois Consumer Fraud and Deceptive Business Practices Act, the Illinois Uniform Deceptive Trade Practices Act, and Defendants' negligence.

**A. Defendants Have Affirmative Duties to Maintain Effective Controls against Diversion of these Dangerous Drugs for Non-Legitimate, Non-Medical Purposes.**

36. Defendant Wholesale Distributors are “one of the key components of the distribution chain. If the closed system is to function properly ... distributors must be vigilant in deciding whether a prospective customer can be trusted to deliver controlled substances only for lawful purposes. This responsibility is critical, as ... the illegal distribution of controlled substances has a substantial and detrimental effect on the health and general welfare of the American people.”<sup>6</sup>

**1. Under both federal law and Illinois law and regulations, Defendants are required to operate a closed system to prevent the diversion of opioids for non-medical purposes.**

37. Opioids are a Schedule II controlled substance under Illinois law. See 720 ILCS 570/206. Opioids are categorized as “Schedule II” drugs because they have a “high potential for abuse” and the potential to cause “severe psychological or physiological dependence.” 720 ILCS 570/205; 21 U.S.C. § 812(b)(2)(A, C).

38. Each Defendant has an affirmative duty under federal and Illinois law to act as a gatekeeper guarding against the diversion of the highly addictive, dangerous opioid drugs. Federal law requires that Distributors of Schedule II drugs, including opioids, must maintain “effective control against diversion of particular controlled substances into other than legitimate medical, scientific, and industrial channels.” 21 U.S.C. § 823(b)(1). Illinois’ minimum requirements for

---

<sup>6</sup> See U.S. Department of Justice, Drug Enforcement Administration, letter to Cardinal Health dated September 27, 2006 (“This letter is being sent to every commercial entity in the United States registered with the Drug Enforcement Agency (DEA) to distribute controlled substances. The purpose of this letter is to reiterate the responsibilities of controlled substance distributors in view of the prescription drug abuse problem our nation currently faces.”) (a copy of letter is filed at *Cardinal Health, Inc. v. Holder*, No. 1:12-cv-00185-RBW, Doc. 14-51 (filed therein in U.S. D.C. on February 20, 2012)).

wholesale drug distribution mandate that “[w]holesale drug distributors shall operate in compliance with applicable federal, state and local laws and regulations.” Ill. Admin. Code Title 68, § 1510.50(i). Wholesale drug distributors licensed in Illinois are also specifically required to comply with all applicable DEA regulations. Ill. Admin. Code Title 68, § 1510.50(i)(2). Moreover, wholesale drug distributors must comply with the regulations promulgated by the Illinois Department of Financial and Professional Regulation, and comply with the wholesale drug distributor licensing guidelines adopted in 21 C.F.R. Part 205. 225 ILCS 120/40.

39. Federal regulations impose a non-delegable duty upon wholesale drug distributors to “design and operate a system to disclose to the registrant suspicious orders of controlled substances. The registrant [distributor] shall inform the Field Division Office of the Administration in his area of suspicious orders when discovered by the registrant. Suspicious orders include orders of unusual size, orders deviating substantially from a normal pattern, and orders of unusual frequency.” 21 C.F.R. § 1301.74(b).

40. In addition to reporting all suspicious orders, distributors must also stop shipment on any order which is flagged as suspicious and only ship orders which were flagged as potentially suspicious if, after conducting due diligence, the distributor can determine that the order is not likely to be diverted into illegal channels. *See Southwood Pharm., Inc.*, 72 Fed. Reg. 36,487, 36,501 (Drug Enf’t Admin. July 3, 2007); *Masters Pharm., Inc. v. Drug Enf’t Admin.*, 861 F.3d 206 (D.C. Cir. 2017). Regardless, all flagged orders must be reported. *Id.*

41. These prescription drugs are regulated for the purpose of providing a “closed” system **intended to reduce the widespread diversion of these drugs out of legitimate channels**

into the illicit market, while at the same time providing the legitimate drug industry with a unified approach to narcotic and dangerous drug control.<sup>7</sup>

42. As wholesale drug distributors, each Defendant was required under Illinois law to first be licensed by the Department of Financial and Professional Regulation. 225 ILCS 120/25. To receive and maintain this license, each of the Defendant Wholesale Distributors assumed a duty to comply with the regulations adopted by the Department of Financial and Professional Regulation and the wholesale drug distributor guidelines in 21 C.F.R. Part 205. 225 ILCS 120/40.

43. Each Defendant was further required to register with the DEA, pursuant to the federal Controlled Substance Act. *See* 21 U.S.C. § 823(b), (e); 28 C.F.R. § 0.100. Each of the Defendant Wholesale Distributors is a “registrant” as a wholesale distributor in the chain of distribution of Schedule II controlled substances with a duty to comply with all security requirements imposed under that statutory scheme. Those requirements are adopted and incorporated into Illinois law. 225 ILCS 120/40; Ill. Admin. Code Title 68, § 1510.50(i).

**2. Defendants were at all relevant times on notice of their duties vis-à-vis suspicious opioid orders.**

44. “Suspicious orders” include orders of an unusual size, orders of unusual frequency or orders deviating substantially from a normal pattern. *See* 21 C.F.R. 1301.74(b). These criteria are disjunctive and are not all inclusive. For example, if an order deviates substantially from a normal pattern, the size of the order does not matter and the order should be reported as suspicious. Likewise, a wholesale distributor need not wait for a normal pattern to develop over time before determining whether a particular order is suspicious. The size of an order alone, regardless of whether it deviates from a normal pattern, is enough to trigger the wholesale distributor’s

---

<sup>7</sup> See 1970 U.S.C.C.A.N. 4566, 4571-72.

responsibility to report the order as suspicious. The determination of whether an order is suspicious depends not only on the ordering patterns of the particular customer but also on the patterns of the entirety of the wholesale distributor's customer base and the patterns throughout the relevant segment of the wholesale distributor industry.

45. Different entities supervise the discrete links in the chain that separate a consumer from a controlled substance. Statutes and regulations carefully define each participant's role and responsibilities. *See Brief for Healthcare Distribution Management Association<sup>8</sup> (HDMA) and National Association of Chain Drug Stores<sup>9</sup> (NACDS) as Amici Curiae in Support of Neither Party, *Masters Pharmaceuticals, Inc. v. U.S. Drug Enforcement Admin.*, 2016 WL 1321983, \*22 (April 4, 2016, filed in D.C. Cir.)* (hereinafter “Brief for HDMA and NACDS”).

46. The Defendant Wholesale Distributors have admitted that they are responsible for reporting suspicious orders.<sup>10</sup>

47. The DEA sent a letter to each of the Defendant Wholesale Distributors on September 27, 2006, warning that it would use its authority to revoke and suspend registrations when appropriate. The letter expressly states that a distributor, *in addition* to reporting suspicious

---

<sup>8</sup> The Healthcare Distribution Management Association (HDMA or HMA) is a national, not-for-profit trade association that represents the nation's primary, full-service healthcare distributors whose membership includes, among others: AmerisourceBergen Drug Corporation, Cardinal Health, Inc., and McKesson Corporation.

<sup>9</sup> The National Association of Chain Drug Stores (NACDS) is a national, not-for-profit trade association that represents traditional drug stores and supermarkets and mass merchants with pharmacies whose membership includes, among others: Walgreen Company, CVS Health, Rite Aid Corporation and Walmart.

<sup>10</sup> *See Brief for HDMA and NACDS, 2016 WL 1321983, \*4, Masters Pharmaceuticals, Inc. v. U.S. Drug Enforcement Admin.* (regulations “in place for more than 40 years require distributors to report suspicious orders of controlled substances to DEA based on information readily available to them (e.g., a pharmacy’s placement of unusually frequent or large orders.”).

orders, has a “statutory responsibility to exercise due diligence to avoid filling suspicious orders that might be diverted into other than legitimate medical, scientific, and industrial channels.”<sup>11</sup> The letter also instructs that “distributors must be vigilant in deciding whether a prospective customer can be trusted to deliver controlled substances only for lawful purposes.”<sup>12</sup> The DEA warns that “even just one distributor that uses its DEA registration to facilitate diversion can cause enormous harm.”<sup>13</sup>

48. The DEA sent a second letter to each of the Defendant Wholesale Distributors on December 27, 2007.<sup>14</sup> This letter reminds the Defendant Wholesale Distributors of their statutory and regulatory duties to “maintain effective controls against diversion” and “design and operate a system to disclose to the registrant suspicious orders of controlled substances.”<sup>15</sup> The letter further explains:

The regulation also requires that the registrant inform the local DEA Division Office of suspicious orders when discovered by the registrant. Filing a monthly report of completed transactions (e.g., “excessive purchase report” or “high unity purchases”) does not meet the regulatory requirement to report suspicious orders. Registrants are reminded that their responsibility does not end merely with the filing of a suspicious order report. Registrants must conduct an independent analysis of suspicious orders prior to completing a sale to determine whether the controlled substances are likely to be diverted from legitimate channels. Reporting an order as suspicious will not absolve the registrant of

---

<sup>11</sup> Letter from Joseph T. Rannazzisi, Deputy Assis. Admin., Office of Diversion Control, to Cardinal Health (Sept. 27, 2006), at page 2 (discussing 21 U.S.C. § 823(e)) (a copy of letter is filed at *Cardinal Health, Inc. v. Holder*, No. 1:12-cv-00185-RBW, Doc. 14-51 (filed in U.S. D.C. on February 20, 2012)).

<sup>12</sup> *Id.*, at page 1.

<sup>13</sup> *Id.*, at page 2.

<sup>14</sup> See Letter from Joseph T. Rannazzisi, Deputy Assis. Admin., Office of Diversion Control, to Cardinal Health (Dec. 27, 2007) (a copy of letter is filed at *Cardinal Health, Inc. v. Holder*, No. 1:12-cv-00185-RBW, Doc. 14-8 (filed in U.S. D.C. on February 20, 2012)).

<sup>15</sup> *Id.*

responsibility if the registrant knew, or should have known, that the controlled substances were being diverted.

The regulation specifically states that suspicious orders include orders of unusual size, orders deviating substantially from a normal pattern, and orders of an unusual frequency. These criteria are disjunctive and are not all inclusive. For example, if an order deviates substantially from a normal pattern, the size of the order does not matter and the order should be reported as suspicious. Likewise, a registrant need not wait for a “normal pattern” to develop over time before determining whether a particular order is suspicious. The size of an order alone, whether or not it deviates from a normal pattern, is enough to trigger the registrant’s responsibility to report the order as suspicious. The determination of whether an order is suspicious depends not only on the ordering patterns of the particular customer, but also on the patterns of the registrant’s customer base and the patterns throughout the segment of the regulated industry.

Registrants that rely on rigid formulas to define whether an order is suspicious may be failing to detect suspicious orders. For example, a system that identifies orders as suspicious only if the total amount of a controlled substance ordered during one month exceeds the amount ordered the previous month by a certain percentage or more is insufficient. This system fails to identify orders placed by a pharmacy if the pharmacy placed unusually large orders from the beginning of its relationship with the distributor. Also, this system would not identify orders as suspicious if the order were solely for one highly abused controlled substance if the orders never grew substantially. Nevertheless, ordering one highly abused controlled substance and little or nothing else deviates from the normal pattern of what pharmacies generally order.

When reporting an order as suspicious, registrants must be clear in their communication with DEA that the registrant is actually characterizing an order as suspicious. Daily, weekly, or monthly reports submitted by registrant indicating “excessive purchases” do not comply with the requirement to report suspicious orders, even if the registrant calls such reports “suspicious order reports.”

Lastly, registrants that routinely report suspicious orders, yet fill these orders without first determining that order is not being diverted into other than legitimate medical, scientific, and industrial channels, may be failing to maintain effective controls against diversion. Failure to maintain effective controls against diversion is inconsistent with the public interest as that term is used in 21 USC 823 and 824, and may result in the revocation of the registrant’s DEA Certificate of Registration.<sup>16</sup>

---

<sup>16</sup> *Id.*

Finally, the DEA letter references the final order issued in *Southwood Pharmaceuticals, Inc.*, 72 FR 36487 (2007) [2007 WL 1886484], which discusses the obligation to report suspicious orders and “some criteria to use when determining whether an order is suspicious.”<sup>17</sup>

49. Defendant Wholesale Distributors “have not only statutory and regulatory responsibilities to detect and prevent diversion of controlled prescription drugs, but undertake such efforts as responsible members of society.”<sup>18</sup>

50. Defendant Wholesale Distributors knew they were required to monitor, detect, report, and refuse to fill suspicious orders. Industry compliance guidelines established by the Healthcare Distribution Management Association, the trade association of pharmaceutical distributors, explain that distributors are “[a]t the center of a sophisticated supply chain” and therefore “are uniquely situated to perform due diligence in order to help support the security of the controlled substances they deliver to their customers.” The guidelines set forth recommended steps in the “due diligence” process, and note in particular: If an order meets or exceeds a distributor’s threshold, as defined in the distributor’s monitoring system, or is otherwise characterized by the distributor as an order of interest, the distributor should not ship to the customer, in fulfillment of that order, any units of the specific drug code product as to which the order met or exceeded a threshold or as to which the order was otherwise characterized as an order of interest.

---

<sup>17</sup> *Id.*

<sup>18</sup> See Amicus Curiae Brief of Healthcare Distribution Management Association in Support of Appellant Cardinal Health, Inc., *Cardinal Health, Inc. v. United States Dept. Justice*, 2012 WL 1637016, \*2 (C.A. D.C.) (May 9, 2012).

**3. At all relevant times, each Defendant was acting under a duty to guard against the diversion of prescription opioids for non-medical purposes.**

51. Each of the Defendant Wholesale Distributors sold prescription opioids, including hydrocodone and/or oxycodone, to retailers in Jersey County, Illinois and/or to retailers from which Defendants knew drugs were likely to be delivered and/or diverted into Jersey County.

52. Defendant Wholesale Distributors owe a duty to maintain effective controls to prevent diversion in Jersey County, including a duty to monitor, detect, report, and refuse to fill suspicious orders of prescription opioids originating from Jersey County, Illinois and/or orders of prescription opioids which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County.

53. Defendant Wholesale Distributors owe a duty to detect suspicious orders of prescription opioids originating from Jersey County, Illinois and/or orders of prescription opioids which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County.

54. Defendant Wholesale Distributors owe a duty to investigate suspicious orders of prescription opioids originating from Jersey County, Illinois and/or orders of prescription opioids which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County. *See Masters Pharmaceuticals, Inc.; Decision and Order*, 80 FR 55418-01, 55477 (September 15, 2015).

55. Defendant Wholesale Distributors owe a duty to refuse suspicious orders of prescription opioids originating from Jersey County, Illinois and/or orders of prescription opioids which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County.

56. Defendant Wholesale Distributors owe a duty to report suspicious orders of prescription opioids originating from Jersey County, Illinois and/or orders of prescription opioids which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County.

57. Defendant Wholesale Distributors owe a duty to maintain effective controls against the diversion of prescription opioids into illicit markets in Jersey County, Illinois.

58. The foreseeable harm resulting from a breach of these duties is the diversion of prescription opioids for nonmedical purposes.

59. The foreseeable harm resulting from the diversion of prescription opioids for nonmedical purposes is abuse, addiction, morbidity and mortality in Jersey County, Illinois, and the damages caused thereby.

#### **B. Deliberately, Knowingly, and for Profit, Defendants Breached Their Duties.**

##### **1. Defendant Wholesale Distributors' Compliance with their legal duties is critical, particularly considering the sharp increase in, and large numbers of, opioid prescriptions.**

60. Because distributors handle such large volumes of controlled substances, and are the first major line of defense in the movement of legal pharmaceutical controlled substances from legitimate channels into the illicit market, it is incumbent on distributors to maintain effective controls to prevent diversion of controlled substances. Should a distributor deviate from these checks and balances, the closed system collapses.<sup>19</sup>

61. The United States consumes opioid pain relievers at a greater rate than any other nation.

---

<sup>19</sup> See Declaration of Joseph Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Agency, United States Department of Justice, ¶10, *Cardinal Health, Inc. v. Holder*, No. 1:12-cv-00185-RBW, Doc. 14-2 (filed in U.S. D.C. on February 20, 2012).

62. The sheer volume of prescription opioids distributed to pharmacies in Jersey County is excessive for the medical need of the community and facially suspicious. Some red flags are so obvious that no one who engages in the legitimate distribution of controlled substances can reasonably claim ignorance of them. *Masters Pharmaceuticals, Inc.; Decision and Order*, 80 FR 55418-01, 55482 (Sept. 15, 2015) (citing *Holiday CVS, L.L.C., d/b/a/CVS/Pharmacy Nos. 219 and 5195*, 77 FR 62,316, 62,322 (2012)); *Masters Pharm., Inc. v. Drug Enf't Admin.*, 861 F.3d 206 (D.C. Cir. 2017).

**2. Defendants breached their duties.**

63. Plaintiffs are of the information and belief that the Defendant Wholesale Distributors failed to report to the DEA “suspicious orders” originating from Jersey County and/or orders of prescription opioids which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County.

64. Plaintiffs allege that the Defendant Wholesale Distributors unlawfully filled suspicious orders of unusual size, orders deviating substantially from a normal pattern and/or orders of unusual frequency in Jersey County, Illinois and/or orders which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County.

65. 720 ILCS 570/205; 225 ILCS 120/40; Ill. Admin. Code Title 68, § 1510.50(i); 21 U.S.C. §§ 812, 823; 21 C.F.R. § 1301.74; 28 C.F.R. § 0.100, and laws and regulations incorporated therein, are public safety laws.

66. The Illinois Legislature’s intent in promulgating the Illinois Controlled Substances Act, Act 570 of Chapter 720, was to effectively:

- (1) limit access of such substances only to those persons who have demonstrated an appropriate sense of responsibility and have a lawful and legitimate reason to possess them;
- (2) deter the unlawful and destructive abuse of controlled substances;
- (3) penalize most heavily the illicit traffickers or profiteers of controlled substances, who propagate and perpetuate the abuse of such substances with reckless disregard

for its consumptive consequences upon every element of society; (4) acknowledge the functional and consequential differences between the various types of controlled substances and provide for correspondingly different degrees of control over each of the various types; (5) unify where feasible and codify the efforts of this State to conform with the regulatory systems of the Federal government; and (6) provide law enforcement authorities with the necessary resources to make this system efficacious.

720 ILCS 570/100.

67. Each Defendant Wholesale Distributor breached its duty to maintain effective controls against diversion of prescription opioids into other than legitimate medical, scientific, and industrial channels.

68. Each Defendant Wholesale Distributor breached its duty to design and operate a system to disclose suspicious orders of controlled substances and failed to inform the DEA of “suspicious orders for drugs when discovered” in violation of 21 C.F.R. § 1301.74(b) and Illinois laws and regulations incorporating federal requirements. 225 ILCS 120/40; Ill. Admin. Code Title 68, § 1510.50(i).

69. Each Defendant Wholesale Distributor breached its duty to provide effective controls and procedures to guard against theft and diversion of controlled substances in violation of Illinois regulations and federal law. *See, e.g.*, 68 Ill. Admin. Code 1510.50; 21 U.S.C. § 823; 21 C.F.R. § 1301.74(b).

70. Defendant Wholesale Distributors’ violations of public safety statutes constitute prima facie evidence of negligence under Illinois law.

71. Defendant Wholesale Distributors breached their duty to exercise due diligence to avoid filling suspicious orders that might be diverted into other than legitimate medical, scientific and industrial channels. *Cardinal Health, Inc. v. Holder*, 846 F. Supp. 2d 203, 206 (D.D.C. 2012).

72. Defendant Wholesale Distributors breached their duty to monitor, detect, investigate, refuse to fill, and report suspicious orders of prescription opioids originating from Jersey County, Illinois and/or which Defendants knew or should have known were likely to be delivered and/or diverted into Jersey County.

### **3. Defendants' serial violations of the law.**

73. As a result of the decade-long refusal by the Defendant Wholesale Distributors to abide by federal law, the DEA has repeatedly taken administrative action to force compliance. The United States Department of Justice, Office of the Inspector General, Evaluation and Inspections Division, reported that the DEA issued final decisions in 178 registrant actions between 2008 and 2012. The Office of Administrative Law Judges issued a recommended decision in a total of 117 registrant actions before the DEA issued its final decision, including 76 actions involving orders to show cause and 41 actions involving immediate suspension orders.<sup>20</sup> These actions include the following:

(a) On April 24, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the AmerisourceBergen Orlando, Florida distribution center ("Orlando Facility") alleging failure to maintain effective controls against diversion of controlled substances. On June 22, 2007, AmerisourceBergen entered into a settlement which resulted in the suspension of its DEA registration;

(b) On November 28, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Auburn, Washington Distribution Center ("Auburn Facility") for failure to maintain effective controls against diversion of hydrocodone;

(c) On December 5, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Lakeland, Florida Distribution Center ("Lakeland Facility") for failure to maintain effective controls against diversion of hydrocodone;

---

<sup>20</sup> *The Drug Enforcement Administration's Adjudication of Registrant Actions*, United States Department of Justice, Office of the Inspector General, Evaluation and Inspections Divisions, I-2014-003 (May 2014).

(d) On December 7, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Swedesboro, New Jersey Distribution Center (“Swedesboro Facility”) for failure to maintain effective controls against diversion of hydrocodone;

(e) On January 30, 2008, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Stafford, Texas Distribution Center (“Stafford Facility”) for failure to maintain effective controls against diversion of hydrocodone;

(f) On May 2, 2008, McKesson Corporation entered into an *Administrative Memorandum of Agreement* (“2008 MOA”) with the DEA which provided that McKesson would “maintain a compliance program designed to detect and prevent the diversion of controlled substances, inform DEA of suspicious orders required by 21 C.F.R. § 1301.74(b), and follow the procedures established by its Controlled Substance Monitoring Program”;

(g) On September 30, 2008, Cardinal Health entered into a *Settlement and Release Agreement and Administrative Memorandum of Agreement* with the DEA related to its Auburn Facility, Lakeland Facility, Swedesboro Facility and Stafford Facility. The document also referenced allegations by the DEA that Cardinal failed to maintain effective controls against the diversion of controlled substances at its distribution facilities located in McDonough, Georgia; Valencia, California; and Denver, Colorado;

(h) On February 2, 2012, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Lakeland, Florida Distribution Center for failure to maintain effective controls against diversion of oxycodone;

(j) On December 23, 2016, Cardinal Health agreed to pay a \$44 million fine to the DEA to resolve the civil penalty portion of the administrative action taken against its Lakeland, Florida Distribution Center; and

(k) On January 5, 2017, McKesson Corporation entered into an *Administrative Memorandum Agreement* with the DEA wherein it agreed to pay a \$150,000,000 civil penalty for violation of the 2008 MOA as well as failure to identify and report suspicious orders at its facilities in Aurora CO, Aurora IL, Delran NJ, LaCrosse WI, Lakeland FL, Landover MD, La Vista NE, Livonia MI, Methuen MA, Santa Fe Springs CA, Washington Courthouse OH and West Sacramento CA.

74. Rather, than abide by their non-delegable duties under public safety statutes, the Defendant Wholesale Distributors, individually and collectively through trade groups in the

industry, pressured the U.S. Dept. of Justice to “halt” prosecutions and lobbied Congress to strip the DEA of its ability to immediately suspend distributor registrations. The result was a “sharp drop in enforcement actions” and the passage of the “Ensuring Patient Access and Effective Drug Enforcement Act” which, ironically, raised the burden for the DEA to revoke a distributor’s license from “imminent harm” to “immediate harm” and provided the industry the right to “cure” any violations of law before a suspension order can be issued.<sup>21</sup>

75. Meanwhile, the opioid epidemic rages unabated in Jersey County, Illinois.

**4. Defendants knowingly breached their mandatory duties.**

76. The epidemic still rages because the fines and suspensions imposed by the DEA do not change the conduct of the Defendant Wholesale Distributors. They pay fines as a cost of doing business in an industry which generates billions of dollars in annual revenue. They hold multiple DEA registration numbers and when one facility is suspended, they simply ship from another facility. And, as bluntly noted by Cardinal Health in its filings in *Cardinal Health, Inc. v. Holder*, 846 F. Supp. 2d 203 (D.D.C. 2012), “suspension … will not address the harm DEA alleges because it will not prevent pharmacies filling illegitimate prescriptions from simply obtaining controlled substances from another distributor.”<sup>22</sup>

77. The Defendant Wholesale Distributors’ repeated shipments of suspicious orders, over an extended period of time, in violation of public safety statutes, and without reporting the

---

<sup>21</sup> See Lenny Bernstein and Scott Higham, Investigation: The DEA slowed enforcement while the opioid epidemic grew out of control, THE WASHINGTON POST (October 22, 2016); Lenny Bernstein and Scott Higham, Investigation: U.S. senator calls for investigation of DEA enforcement slowdown amid opioid crisis, THE WASHINGTON POST (March 6, 2017); *Eric Eyre, DEA agent: ‘We had no leadership’ in WV amid flood of pain pills*, Charleston Gazette (February 18, 2017).

<sup>22</sup> Memorandum of Points of Authorities in Support of Cardinal Health’s Motion for Temporary Restraining Order (Doc. 3-1), at p. 22, *Cardinal Health, Inc. v. Holder*, No. 1:12-cv-00185-RBW (D.C. Cir. Feb. 3, 2012).

suspicious orders to the relevant authorities, demonstrates wanton, willful, or reckless conduct or criminal indifference to civil obligations affecting the rights of others and justifies an award of punitive damages.

78. The unlawful conduct by the Defendant Wholesale Distributors is purposeful and intentional. Bluntly, they refuse to abide by the duties imposed by law which are required to maintain an Illinois license to distribute prescription opioids and to maintain their DEA registration. Defendants acted with actual malice, *i.e.*, Defendants acted with a conscious disregard for the rights and safety of other persons, and said actions have a great probability of causing substantial harm. Defendants acted willfully. Defendants acted with such gross negligence as to indicate a wanton disregard of the rights of others. Punitive damages are necessary to deter similar conduct in the future.

79. Defendant Wholesale Distributors have publicly disavowed any duty beyond *reporting* suspicious orders and, even then, have claimed they were not required to report all suspicious orders. In *Masters Pharmaceuticals, Inc. v. U.S. Drug Enforcement Admin.*, 2016 WL 1321983 (D.C. Cir. April 4, 2016), the Healthcare Distribution Management Association and National Association of Chain Drug Stores submitted amicus briefs regarding the legal duty of wholesale distributors. Inaccurately denying the legal duties that the wholesale drug industry has been tragically recalcitrant in performing, they argued that:

- The Associations complained that the “DEA has required distributors not only to report suspicious orders, but to *investigate* orders (e.g., by interrogating pharmacies and physicians) and take action to *halt* suspicious orders before they are filled.” (emphasis in original) (Brief for HDMA and NACDS, 2016 WL 1321983, at \*\* 4-5);
- The Associations argued that, “DEA now appears to have changed its position to require that distributors not only *report* suspicious orders, but *investigate* and *halt* suspicious orders. Such a change in agency position must be accompanied by an acknowledgment of the change and a reasoned

explanation for it. In other words, an agency must display awareness that it is changing position and show that there are good reasons for the new policy. This is especially important here, because imposing intrusive obligation on distributors threatens to disrupt patient access to needed prescription medications.” (internal citations & quotes omitted) (emphasis in original) (*Id.*, at \*8);

- The Associations alleged (inaccurately) that nothing “requires distributors to investigate the legitimacy of orders, or to halt shipment of any orders deemed to be suspicious.” (*Id.*, at \*14);
- The Association complained that the purported “practical infeasibility of requiring distributors to investigate and halt suspicious orders (as well as report them) underscores the importance of ensuring that DEA has complied with the APA before attempting to impose such duties.” (*Id.*, at \*22);
- The Associations alleged (inaccurately) that “DEA’s regulations [] sensibly impose[] a duty on distributors simply to *report* suspicious orders, but left it to DEA and its agents to investigate and halt suspicious orders.” (emphasis in original) (*Id.*, at \*\*24-25); and,
- Also inaccurately, the Associations argued that, “[i]mposing a duty on distributors - which lack the patient information and the necessary medical expertise – to investigate and halt orders may force distributors to take a shot-in-the-dark approach to complying with DEA’s demands.” (*Id.*, at \*26).

80. The positions taken by the trade groups is emblematic of the position taken by the Defendant Wholesale Distributors in a futile attempt to deny their legal obligations to prevent diversion of the dangerous drugs.<sup>23</sup>

81. The Court of Appeals for the District of Columbia recently issued its opinion affirming that a wholesale drug distributor does, in fact, have a duty to report all suspicious orders and also has duties beyond reporting. *Masters Pharmaceutical, Inc. v. Drug Enf’t Admin.*, 861 F.3d 206 (D.C. Cir. 2017). The Circuit Court upheld the revocation of Masters Pharmaceutical’s

---

<sup>23</sup> See Amicus Curiae Brief of HDMA, *Cardinal Health, Inc. v. United States Dept. Justice*, 2012 WL 1637016, at \*3 (arguing the wholesale distributor industry “does not know the rules of the road” because they claim (inaccurately) that the “DEA has not adequately explained them.”).

license and determined that DEA regulations require that in addition to reporting suspicious orders, distributors “must . . . decline to ship the order, or conduct some ‘due diligence’ and—if it is able to determine that the order is not likely to be diverted into illegal channels—ship the order.” 861 F.3d at 212-13 Masters Pharmaceutical was in violation of legal requirements not only because it failed to report suspicious orders, but also because it failed to conduct necessary investigations and filled suspicious orders. *Id.* at 217-19, 222-23. Before a distributor may ship a suspicious order, a distributor’s investigation must dispel all red flags giving rise to suspicious circumstance. *Id.* at 222-23. The Circuit Court also rejected the argument made by the Healthcare Distribution Management Association and National Association of Chain Drug Stores, that, allegedly, the DEA had created or imposed new duties. *Id.* at 221-22.

82. Wholesale Distributor McKesson has specifically admitted to breaching its duties to monitor, report, and prevent suspicious orders. Pursuant to an Administrative Memorandum of Agreement (“2017 Agreement”) entered into between McKesson and the DEA in January 2017, McKesson admitted that, at various times during the period from January 1, 2009 through the effective date of the Agreement (January 17, 2017) it “did not identify or report to [the] DEA certain orders placed by certain pharmacies which should have been detected by McKesson as suspicious based on the guidance contained in the DEA Letters about the requirements set forth in 21 C.F.R. § 1301.74(b) and 21 U.S.C. § 842(a)(5).”<sup>24</sup> Further, the 2017 Agreement specifically finds that McKesson “distributed controlled substances to pharmacies even though those McKesson Distribution Centers should have known that the pharmacists practicing within those pharmacies had failed to fulfill their corresponding responsibility to ensure that controlled

---

<sup>24</sup> See Administrative Memorandum of Agreement between the United States Department of Justice, the Drug Enforcement Agency, and McKesson Corporation, effective date January 17, 2017.

substances were dispensed pursuant to prescriptions issued for legitimate medical purposes by practitioners acting in the usual course of their professional practice, as required by 21 C.F.R § 1306.04(a).”<sup>25</sup> McKesson admitted that, during this time period, it “failed to maintain effective controls against diversion of particular controlled substances into other than legitimate medical, scientific and industrial channels by sales to certain of its customers in violation of the CSA and the CSA's implementing regulations, 21 C.F.R. Part 1300 et seq., at the McKesson Distribution Centers” including the McKesson Distribution Center located in “Aurora, Illinois.”<sup>26</sup>

83. The 2017 Memorandum of Agreement followed a 2008 Settlement Agreement in which McKesson also admitted failure to report suspicious orders of controlled substances to the DEA.<sup>27</sup> In the 2008 Settlement Agreement, McKesson “recognized that it had a duty to monitor its sales of all controlled substances and report suspicious orders to DEA,” but had failed to do so.<sup>28</sup> The 2017 Memorandum of Agreement documents that McKesson continued to breach its admitted duties by “fail[ing] to properly monitor its sales of controlled substances and/or report suspicious orders to DEA, in accordance with McKesson's obligations under the 2008 Agreements, the Act, and 21 C.F.R. § 1301.74(b).”<sup>29</sup> The 2017 Memorandum of Agreement and the associated

---

<sup>25</sup> *Id.* at 4.

<sup>26</sup> *Id.* at 3.

<sup>27</sup> *Id.* at 4.

<sup>28</sup> *Id.*

<sup>29</sup> *Id.* at 4. *See also* Settlement Agreement and Release between the United State of America (acting through the Department of Justice and on behalf of the Drug Enforcement Administration) and McKesson Corporation, effective date January 17, 2017 (“2017 Settlement Agreement and Release”) (“McKesson acknowledges that, at various times during the Covered Time Period [2009-2017], it did not identify or report to DEA certain orders placed by certain pharmacies, which should have been detected by McKesson as suspicious, in a manner fully consistent with the requirements set forth in the 2008 MOA.”).

Settlement Agreement and Release revealed to the public that McKesson was not complying with the 2008 Settlement Agreement. As a result of these violations, McKesson was fined and required to pay to the United States \$150,000,000.<sup>30</sup>

**C. The Opioid Plague in Jersey County, Illinois, Was Caused by, and Is the Proximate Result of, Defendants' Breaches of Mandatory Duties to Maintain Effective Controls to Prevent the Diversion of Dangerous, Highly Addictive Opioids.**

84. Defendant Wholesale Distributors' failure to monitor, detect, investigate, refuse to fill, and report suspicious orders is a direct and proximate *cause* of the diversion of millions of doses of prescription opioids into the illicit market for purposes other than legitimate medical use in Jersey County, Illinois.

85. The unlawful conduct by Defendant Wholesale Distributors *caused* the very harm the federal and Illinois statutes and regulations were intended to prevent; namely, the diversion of prescription opioids for illegitimate and/or nonmedical purposes.

86. The unlawful diversion of prescription opioids is a direct and proximate *cause* of prescription opioid abuse, addiction, morbidity and mortality in Jersey County, Illinois.

87. The unlawful diversion of prescription opioids is a direct and proximate *cause* of the prescription opioid epidemic currently plaguing Jersey County, Illinois.

88. The unlawful diversion of prescription opioids is a direct and proximate *cause* of the heroin epidemic currently plaguing Jersey County, Illinois.

89. Opioid analgesics are widely diverted and improperly used, and the widespread use of the drugs has resulted in a national epidemic of opioid overdose deaths and addictions.<sup>31</sup>

---

<sup>30</sup> See 2017 Settlement Agreement and Release at p. 6.

<sup>31</sup> See Nora D. Volkow, M.D. and A. Thomas McLellan, Ph.D., *Opioid Abuse in Chronic Pain—Misconceptions and Mitigation Strategies*, NEW ENG. J. MED., 374;1253-63 (March 31, 2016).

90. The epidemic is “directly related to the increasingly widespread misuse of powerful opioid pain medications.”<sup>32</sup>

91. The increased use of prescription painkillers for reasons other than legitimate medical use (for the high they cause), along with growing sales, has contributed to a large number of overdoses and deaths.<sup>33</sup>

92. There is “a parallel relationship between the availability of prescription opioid analgesics through legitimate pharmacy channels and the diversion and abuse of these drugs and associated adverse outcomes.”<sup>34</sup>

93. The CDC has identified addiction to prescription pain medication as the strongest risk factor for heroin addiction. People who are addicted to prescription opioids are forty times more likely to be addicted to heroin.<sup>35</sup>

94. Heroin is pharmacologically similar to prescription opioids. The majority of current heroin users report having used prescription opioids non-medically before they initiated heroin use. Available data indicates that the nonmedical use of prescription opioids is a strong risk factor for heroin use.<sup>36</sup> The CDC reports that drug overdose deaths involving heroin continued

---

<sup>32</sup> See Special Report, FDA Commissioner Robert M. Califf, M.D., et al., *A Proactive Response to Prescription Opioid Abuse*, NEW ENGL. J. MED., 374;1480-85 (April 14, 2016).

<sup>33</sup> See Press Release, *Prescription painkiller overdoses at epidemic levels*, U.S. Department of Health and Human Resources, Centers for Disease Control and Prevention (November 1, 2011).

<sup>34</sup> See Richard C. Dart, M.D., Ph.D., et al., *Trends in Opioid Analgesic Abuse and Mortality in the United States*, NEW ENGL. J. MED., 372;241-248, 245 (January 15, 2015).

<sup>35</sup> See CDC Vital Signs Fact Sheet, *Today’s Heroin Epidemic*, U.S. Department of Health and Human Resources, Centers for Disease Control and Prevention (July 2015).

<sup>36</sup> See Wilson M. Compton, M.D., M.P.E., et al., *Relationship between Nonmedical Prescription Opioid Use and Heroin Use*, NEW ENG. J. MED., 374;154-63 (January 14, 2016).

to climb sharply, with heroin overdoses more than tripling in 4 years. This increase mirrors large increases in heroin use across the country and has been shown to be closely tied to opioid pain reliever misuse and dependence. ***Past misuse of prescription opioids is the strongest risk factor for heroin initiation and use***, specifically among persons who report past-year dependence or abuse.

**D. Defendants' Misrepresentations and Fraudulent Intent.**

95. Defendants' intent to violate the law and engage in an enterprise to drive up their profits from and sales of diverted opioids is evident from: (1) Defendants' repeated violations of the law, including notices of violations and settlements; (2) Defendants' failures to adequately implement stated anti-diversion policies; (3) Defendants' failures to adequately fund anti-diversion efforts; and (4) Defendants' continued and ongoing maintenance of a corporate structure that rewards increases in opioid sales and encourages the distributors' employees/agents to turn a blind eye to suspicious conduct.

96. To protect their registered distributor status with the Illinois Department of Finance and Professional Regulation and DEA, so that they can continue to generate profits, the Defendant Wholesale Distributors undertook efforts to fraudulently assure the public that they were in fact complying with their legal obligations. Through such statements, the Distributors attempted to assure the public they are working to curb the opioid epidemic.

97. For example, a Cardinal Health executive claimed that it uses "advanced analytics" to monitor its supply chain, and assured the public it was being "as effective and efficient as possible in constantly monitoring, identifying, and eliminating any outside criminal activity."<sup>37</sup>

---

<sup>37</sup> Lenny Bernstein *et al.*, How drugs intended for patients ended up in the hands of illegal users: 'No one was doing their job', THE WASHINGTON POST, October 22, 2016, available at <https://www.washingtonpost.com/investigations/how-drugs-intended-for-patients-ended-up-in->

Given the sales volumes and the company's history of violations, this executive was either not telling the truth, or Cardinal Health had such a system, but it ignored the results.

98. Similarly, Defendant McKesson publicly stated that it has a “best-in-class controlled substance monitoring program to help identify suspicious orders,” and claimed it is “deeply passionate about curbing the opioid epidemic in our country.”<sup>38</sup> Again, given McKesson’s historical conduct, this statement is either false, or the company ignored outputs of the monitoring program.

99. Moreover, through their participation in the Healthcare Distribution Management Association (“HDMA”), the trade association of pharmaceutical distributors, the Distributors admit that they are “[a]t the center of a sophisticated supply chain” and therefore “are uniquely situated to perform due diligence in order to help support the security of the controlled substances they deliver to their customers.”<sup>39</sup> The Distributors state the HDMA Guidelines “were prepared in recognition of the growing problem of misuse and diversion of Controlled Substances (CS) and the critical role of each member of the supply chain in helping to enhance security.”<sup>40</sup> Given Defendants’ ability to know where opioids are being sent and how order volumes change year after

---

[the-hands-of-illegal-users-no-one-was-doing-their-job/2016/10/22/10e79396-30a7-11e6-8ff7-7b6c1998b7a0\\_story.html?utm\\_term=.744e85035bdc](https://www.washingtonpost.com/investigations/the-hands-of-illegal-users-no-one-was-doing-their-job/2016/10/22/10e79396-30a7-11e6-8ff7-7b6c1998b7a0_story.html?utm_term=.744e85035bdc) (last visited July 12, 2017).

<sup>38</sup> Scott Higham *et al.*, Drug industry hired dozens of officials from the DEA as the agency tried to curb opioid abuse, THE WASHINGTON POST, December 22, 2016, available at [https://www.washingtonpost.com/investigations/key-officials-switch-sides-from-dea-to-pharmaceutical-industry/2016/12/22/55d2e938-c07b-11e6-b527-949c5893595e\\_story.html?utm\\_term=.68a58d17478e](https://www.washingtonpost.com/investigations/key-officials-switch-sides-from-dea-to-pharmaceutical-industry/2016/12/22/55d2e938-c07b-11e6-b527-949c5893595e_story.html?utm_term=.68a58d17478e) (last visited July 12, 2017).

<sup>39</sup> See Healthcare Distribution Management Association (HDMA) Industry Compliance Guidelines: Reporting Suspicious Orders and Preventing Diversion of Controlled Substances (dated in or around 2012) (“HDMA Guidelines”).

<sup>40</sup> *Id.*

year, they are well aware of their unique ability to identify suspicious sales volumes and patterns, but nonetheless chose not to report suspicious orders or take any actions to refuse to fill suspicious orders.

**E. Jersey County and the Public Welfare Have Been Damaged by Defendants' Participation in the Unlawful Diversion of Dangerous, Highly Addictive Opioids.**

**1. Opioid-related addiction and death has reached epidemic proportions.**

100. The number of annual opioid prescriptions written in the United States is now roughly equal to the number of adults in the population.<sup>41</sup>

101. Many Americans are now addicted to prescription opioids, and the number of deaths due to prescription opioid overdose is unacceptable. In 2014 there were almost 19,000 overdose deaths in the United States associated with prescription opioids.<sup>42</sup>

102. Barack Obama, then President of the United States, declared a prescription opioid and heroin epidemic.<sup>43</sup>

103. Among 47,055 drug overdose deaths that occurred in 2014 in the United States, 28,647 (60.9%) involved an opioid.<sup>44</sup>

---

<sup>41</sup> See Robert M. Califf, M.D., et al., *A Proactive Response to Prescription Opioid Abuse*, NEW ENGL. J. MED., 374;1480 (April 14, 2016).

<sup>42</sup> *Id.*

<sup>43</sup> See Barack Obama, President of the United States, Proclamation 9499, *Prescription Opioid and Heroin Epidemic Awareness Week*, 2016, 81 FR 65173 (September 16, 2016).

<sup>44</sup> See Rose A. Rudd, MSPH, et al., *Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015*, Morbidity and Mortality Weekly Report (MMWR), Centers for Disease Control and Prevention, 65(50-51);1445–1452 (December 30, 2016).

104. Fundamentally, prescription opioids and heroin are elements of a larger epidemic of opioid-related disorders and death. Viewing them from a unified perspective is essential to improving public health.<sup>45</sup>

**2. While the opioid epidemic is a national tragedy, the statistics are particularly tragic in Illinois and Jersey County.**

105. Drug overdose deaths and opioid-involved deaths continue to increase in the United States. The majority of drug overdose deaths (more than six out of ten) involve an opioid.<sup>46</sup>

106. From 2000 to 2015 more than half a million people died from drug overdoses. 91 Americans die every day from an opioid overdose.<sup>47</sup>

107. Overdoses from prescription opioids are a driving factor in the increase in opioid overdose deaths. Since 1999, the amount of prescription opioids sold in the U.S. nearly quadrupled, yet there has not been an overall change in the amount of pain that Americans report.<sup>48</sup>

108. Since 1999, the number of overdose deaths involving opioids (including prescription opioid pain relievers and heroin) nearly quadrupled in the United States.<sup>49</sup>

109. Illinois has been devastated by the opioid epidemic. In Illinois, more people died from an opioid drug overdose in 2014 than from homicide or motor vehicle accidents. Opioid drug

---

<sup>45</sup> See Wilson M. Compton, M.D., M.P.E., et al., *Relationship between Nonmedical Prescription Opioid Use and Heroin Use*, NEW ENGL. J. MED., 374;154 (Jan. 14, 2016).

<sup>46</sup> Understanding the Epidemic, Drug overdose deaths in the United States continue to increase in 2015, Centers for Disease Control and Prevention, available at <https://www.cdc.gov/drugoverdose/epidemic/index.html> (last visited Aug. 8, 2017).

<sup>47</sup> *Id.*

<sup>48</sup> *Id.*

<sup>49</sup> See Prescription Opioids and Heroin, Illinois Department of Public Health, available at <http://www.dph.illinois.gov/topics-services/prevention-wellness/prescription-opioids-and-heroin> (last visited Aug. 8, 2017).

overdoses killed 45% more people than homicide. Opioid drug overdoses killed 25% more people than motor vehicle crashes. And, opioid drug overdoses killed more people than gun-related causes.<sup>50</sup>

110. Illinois is one of the States identified by the United States Center for Disease Control and Prevention (CDC) as having a statistically significant drug overdose death rate increase from 2014 to 2015, and from 2013 to 2014.<sup>51</sup> The percent increase from 2014 to 2015 was 7.6%, and the percent increase from 2013 to 2014 was 8.3%.<sup>52</sup>

111. The opioid epidemic is occurring in Jersey County. The CDC has tracked prescription rates per County in the United States, identifying the geographic “hotspots” for rates of opioid prescriptions.<sup>53</sup> The CDC has calculated the geographic distribution at county levels of opioid prescriptions dispensed per 100 persons,<sup>54</sup> revealing that Jersey has been a consistent hotspot over at least the past decade.

112. The CDC’s statistics prove that the opioid prescription rates in this County have exceeded any legitimate medical, scientific, or industrial purpose. The overall opioid prescribing rate in 2016 was 66.5 prescriptions per 100 people.<sup>55</sup> However, in Jersey County Illinois, the 2016

---

<sup>50</sup> *Id.*

<sup>51</sup> Drug Overdose Death Data, CDC, available at <https://www.cdc.gov/drugoverdose/data/statedeaths.html> (last visited Aug. 8, 2017).

<sup>52</sup> *Id.*

<sup>53</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>54</sup> *Id.*

<sup>55</sup> *Id.*

prescription rate was 117.9 per 100 people – a rate of more than one prescription for every person.<sup>56</sup>

The 2016 County prescription rate constituted an increase from 107.9 per 100 people in Jersey County in 2015.<sup>57</sup>

113. Unfortunately, the 2015 and 2016 high rates of opioid prescriptions were not an aberration for this County. Consistently, the opioid prescribing rates in the County have been greater than one prescription per person, and significantly greater than the national average. Compared to a national average of 75.6 per 100 people in 2014,<sup>58</sup> 109.2 per 100 people in Jersey County were prescribed opioids in 2014.<sup>59</sup> Compared to a national average of 78.1 per 100 people in 2013,<sup>60</sup> 114.3 per 100 people in Jersey County were prescribed opioids in 2013.<sup>61</sup> Compared to a national average of 81.3 per 100 people in 2012,<sup>62</sup> 113.2 per 100 people in Jersey County were

---

<sup>56</sup> U.S. County Prescribing Rates, 2016, CDC available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2016.html> (last visited Aug. 8, 2017).

<sup>57</sup> U.S. County Prescribing Rates, 2015, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2015.html> (last visited Aug. 8, 2017).

<sup>58</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>59</sup> U.S. County Prescribing Rates, 2014, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2014.html> (last visited Aug. 8, 2017).

<sup>60</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>61</sup> U.S. County Prescribing Rates, 2013, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2013.html> (last visited Aug. 8, 2017).

<sup>62</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

prescribed opioids in 2012.<sup>63</sup> Compared to a national average of 80.9 per 100 people in 2011,<sup>64</sup> 131.1 per 100 people in Jersey County were prescribed opioids in 2011.<sup>65</sup> Compared to a national average of 81.2 per 100 people in 2010,<sup>66</sup> 133.7 per 100 people in Jersey County were prescribed opioids in 2010.<sup>67</sup> Compared to a national average of 79.5 per 100 people in 2009,<sup>68</sup> 108.4 per 100 people in Jersey County were prescribed opioids in 2009.<sup>69</sup> Compared to a national average of 78.2 per 100 people in 2008,<sup>70</sup> 100.2 per 100 people in Jersey County were prescribed opioids in 2008.<sup>71</sup>

---

<sup>63</sup> U.S. County Prescribing Rates, 2012, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2012.html> (last visited Aug. 8, 2017).

<sup>64</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>65</sup> U.S. County Prescribing Rates, 2011, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2011.html> (last visited Aug. 8, 2017).

<sup>66</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>67</sup> U.S. County Prescribing Rates, 2010, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2010.html> (last visited Aug. 8, 2017).

<sup>68</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>69</sup> U.S. County Prescribing Rates, 2009, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2009.html> (last visited Aug. 8, 2017).

<sup>70</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>71</sup> U.S. County Prescribing Rates, 2008, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2008.html> (last visited Aug. 8, 2017).

Compared to a national average of 75.9 per 100 people in 2007,<sup>72</sup> 106.3 per 100 people in Jersey County were prescribed opioids in 2007.<sup>73</sup>

114. The tragic opioid epidemic impacts infants. The use of opiates during pregnancy can result in a drug withdrawal syndrome in newborns called Neonatal Abstinence Syndrome (NAS). There was a five-fold increase in the proportion of babies born with NAS from 2000 to 2012, when an estimated 21,732 infants were born with NAS —equivalent to one baby suffering from opiate withdrawal born every 25 minutes.<sup>74</sup> The cost of treating these infants is significant. Newborns with NAS were more likely than other babies to also have low birthweight and respiratory complications. In 2012, newborns with NAS stayed in the hospital an average of 16.9 days (compared to 2.1. days for other newborns).<sup>75</sup> Thus, the epidemic has placed increased budgetary constraints upon *inter alia* the County’s public health and medical care expenditures.

115. Opioid addiction is a primary reason that Illinois citizens seek substance abuse treatment. Thus, the epidemic has placed increased budgetary costs upon the County’s services and expenditures.

116. Criminal charges associated with the diversion of opioids have increased. This has placed increased budgetary costs upon the County’s criminal law enforcement expenses.

---

<sup>72</sup> U.S. Prescribing Rate Maps, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited Aug. 8, 2017).

<sup>73</sup> U.S. County Prescribing Rates, 2007, CDC, available at <https://www.cdc.gov/drugoverdose/maps/rxcounty2007.html> (last visited Aug. 8, 2017)..

<sup>74</sup> Dramatic Increases in maternal Opioid Use and Neonatal Abstinence Syndrome, NIH National Institute on Drug Abuse, available at <https://www.drugabuse.gov/related-topics/trends-statistics/infographics/dramatic-increases-in-maternal-opioid-use-neonatal-abstinence-syndrome> (last visited Aug. 8, 2017).

<sup>75</sup> *Id.*

117. Prescription opioid abuse, addiction, morbidity, and mortality are hazards to public health and safety in Jersey County, Illinois.

118. Prescription opioid abuse, addiction, morbidity, and mortality are a temporary public nuisance in Jersey County, Illinois, which remains unabated.

119. Heroin abuse, addiction, morbidity, and mortality are hazards to public health and safety in Jersey County, Illinois.

120. Heroin abuse, addiction, morbidity, and mortality are a temporary public nuisance in Jersey County, Illinois, which remains unabated.

121. To eliminate the hazard to public health and safety, and abate the public nuisance, a “multifaceted, collaborative public health and law enforcement approach is urgently needed.”<sup>76</sup>

122. “A comprehensive response to this crisis must focus on preventing new cases of opioid addiction, identifying early opioid-addicted individuals, and ensuring access to effective opioid addiction treatment while safely meeting the needs of patients experiencing pain.”<sup>77</sup>

### **3. General declaration of damages applicable to all Counts herein.**

123. The unlawful conduct by the Defendant Wholesale Distributors has created hazards to public health and safety and a temporary public nuisance in Jersey County, Illinois, which remains unabated.

---

<sup>76</sup> See Rose A. Rudd, MSPH, et al, *Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015*, Morbidity and Mortality Weekly Report (MMWR), Centers for Disease Control and Prevention, 65(50-51);1445–1452 (December 30, 2016).

<sup>77</sup> See Alexander GC, Frattaroli S, Gielen AC, eds. *The Prescription Opioid Epidemic: An Evidence-Based Approach*, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland: 2015, available at <http://www.jhsph.edu/research/centers-and-institutes/johns-hopkins-center-for-injury-research-and-policy/publications-resources/CenterPubs/2015-prescription-opioid-epidemic-report.pdf> (last visited Aug. 10, 2017).

124. Plaintiffs seek economic damages from the Defendant Wholesale Distributors as reimbursement for the costs association with past efforts to eliminate the hazards to public health and safety.

125. Plaintiffs seek economic damages from the Defendant Wholesale Distributors to pay for the damages incurred and the future costs required to permanently eliminate the hazards to public health and safety and abate the temporary public nuisance.

126. Plaintiffs seek to hold the Defendant Wholesale Distributors financially responsible for the economic costs of eliminating the hazards to public health and safety and abating the temporary public nuisance caused by the unlawful conduct recited herein.

127. Plaintiffs seek punitive damages to deter the Defendant Wholesale Distributors and others from committing like offenses in the future. Defendants acted with actual malice, willfully, and with such gross negligence as to indicate a wanton disregard for the rights of others, and said actions have a great probability of causing substantial harm.

#### **F. Tolling of the Statute of Limitations and Estoppel**

128. Plaintiffs contend that the harm caused by the unlawful actions of the Defendant Wholesale Distributors continues.

129. The continued tortious conduct by the Defendant Wholesale Distributors causes a repeated or continuous injury. The damages have not occurred all at once but have increased as time progresses. The tort is not completed nor have all the damages been incurred until the wrongdoing ceases. The wrongdoing has not ceased. The public nuisance remains unabated.

130. Plaintiffs' claims are subject to both equitable estoppel, stemming from Defendant Wholesale Distributors' knowingly and fraudulently concealing the facts alleged herein, and equitable tolling, stemming from Defendants' wrongful concealment and from Plaintiffs' inability to obtain vital information underlying its claims.

**1. Defendants Deliberately Concealed Their Misconduct and Misrepresented their Compliance with their Legal Obligations.**

131. Defendants are estopped from relying upon a statute of limitations defense because the Distributors undertook efforts to purposefully conceal their unlawful conduct and fraudulently assure the public that they were undertaking efforts to comply with their obligations under the CSA. Separate and apart from Defendants' acts of concealment, any applicable statutes of limitation are properly tolled because Plaintiffs did not know and could not have learned the true facts underlying their claims until shortly before filing its Complaint.

132. Indeed, Defendant Wholesale Distributors are estopped by their own fraudulent concealment from asserting the statute of limitations as an affirmative defense against Plaintiffs' claims.

133. Defendants misrepresented their compliance with the law and prevented discovery by the public and by the Plaintiffs of their wrongful actions.

134. Notwithstanding the allegations set forth above, the Defendant Wholesale Distributors affirmatively assured the public they are working to curb the opioid epidemic.

135. For example, a Cardinal Health executive claimed that it uses "advanced analytics" to monitor its supply chain, and assured the public it was being "as effective and efficient as possible in constantly monitoring, identifying, and eliminating any outside criminal activity."<sup>78</sup> Given the sales volumes and the company's history of violations, this executive was either not telling the truth, or Cardinal Health had such a system, but it ignored the results.

---

<sup>78</sup> Lenny Bernstein, et al., How drugs intended for patients ended up in the hands of illegal users: 'No one was doing their job', THE WASHINGTON POST, October 22, 2016, available at [https://www.washingtonpost.com/investigations/how-drugs-intended-for-patients-ended-up-in-the-hands-of-illegal-users-no-one-was-doing-their-job/2016/10/22/10e79396-30a7-11e6-8ff7-7b6c1998b7a0\\_story.html?utm\\_term=.744e85035bdc](https://www.washingtonpost.com/investigations/how-drugs-intended-for-patients-ended-up-in-the-hands-of-illegal-users-no-one-was-doing-their-job/2016/10/22/10e79396-30a7-11e6-8ff7-7b6c1998b7a0_story.html?utm_term=.744e85035bdc) (last visited June 16, 2017).

136. Similarly, McKesson publicly stated that it has a “best-in-class controlled substance monitoring program to help identify suspicious orders,” and claimed it is “deeply passionate about curbing the opioid epidemic in our country.”<sup>79</sup> It was only in January 2017 that the agreement accompanying the \$150,000,000 fine against McKesson revealed that McKesson was, yet again, violating its legal obligations to maintain effective controls against diversion, including through monitoring, reporting and preventing distribution of suspicious orders.

137. Additionally, even though the Defendant Wholesale Distributors entered into settlements and consent orders, outside of certain limited admissions made in those recently publicized documents, Defendants have not admitted liability or any wrongdoing. On the contrary, in connection with these settlements, the Defendant Wholesale Distributors have repeatedly contended they were in compliance with the law.

138. Moreover, in furtherance of their effort to affirmatively conceal their conduct and avoid detection, the Defendant Wholesale Distributors, through their trade associations, Healthcare Distribution Management Association (HDMA) and National Association of Chain Drug Stores (NACDS), filed an *Amicus* brief in *Masters Pharmaceuticals, Inc. v. U.S. Drug Enforcement Administration*, Case No. 15-1335; 2016 WL 1321983 (D.C. Cir. Apr. 4, 2016), which made the following statements:

- “HDMA and NACDS members not only have statutory and regulatory responsibilities to guard against diversion of controlled prescription drugs, but undertake such efforts as responsible members of society.”

---

<sup>79</sup> Scott Higham, et al., Drug industry hired dozens of officials from the DEA as the agency tried to curb opioid abuse, THE WASHINGTON POST, December 22, 2016, available at [https://www.washingtonpost.com/investigations/key-officials-switch-sides-from-dea-to-pharmaceutical-industry/2016/12/22/55d2e938-c07b-11e6-b527-949c5893595e\\_story.html?utm\\_term=.68a58d17478e](https://www.washingtonpost.com/investigations/key-officials-switch-sides-from-dea-to-pharmaceutical-industry/2016/12/22/55d2e938-c07b-11e6-b527-949c5893595e_story.html?utm_term=.68a58d17478e) (last visited June 16, 2017).

- “DEA regulations that have been in place for more than 40 years require distributors to *report* suspicious orders of controlled substances to DEA based on information readily available to them (e.g., a pharmacy's placement of unusually frequent or large orders).”
- “Distributors take seriously their duty to report suspicious orders, utilizing both computer algorithms and human review to detect suspicious orders based on the generalized information that *is* available to them in the ordering process.”
- “A particular order or series of orders can raise red flags because of its unusual size, frequency, or departure from typical patterns with a given pharmacy.”
- “Distributors also monitor for and report abnormal behavior by pharmacies placing orders, such as refusing to provide business contact information or insisting on paying in cash.”

Through the above statements made on their behalf by their trade associations, the Defendant Wholesale Distributors not only acknowledged that they understood their obligations under the law, but they further affirmatively represented that their conduct was in compliance with those obligations.

139. In light of their statements to the media, in legal filings, and in settlements, it is clear that Defendant Wholesale Distributors had actual or constructive knowledge that their conduct was deceptive, in that they consciously concealed the schemes set forth herein.

140. The County has diligently sought to discover and prevent the causes of the opioid-based public nuisance in Jersey County.

141. Defendants’ actions were affirmatively designed to prevent, and did prevent, discovery of the County’s cause of action. Defendants’ actions constituted actual artifice to prevent knowledge of the facts. Defendants committed affirmative acts of concealment and misrepresentation to exclude suspicion and prevent inquiry.

142. Plaintiffs reasonably relied on Defendants’ affirmative statements regarding their purported compliance with their obligations under the law and consent orders.

143. The purposes of the statutes of limitations period are satisfied because Defendants cannot claim prejudice due to a late filing where Plaintiffs filed suit promptly upon discovering the facts essential to its claims, described herein, which Defendants knowingly concealed.

144. Defendants continually and secretly engaged in their scheme to avoid compliance with their reporting obligations. Only Defendants and their agents knew or could have known about Defendants' unlawful failure to report suspicious sales because Defendants made deliberate efforts to conceal their conduct. As a result of the above, Plaintiffs were unable to obtain vital information bearing on their claims absent any fault or lack of diligence on Plaintiffs' part.

## **2. Defendant Wholesale Distributors' Conduct Is Exposed.**

145. On December 17, 2016, the Charleston Gazette-Mail published a groundbreaking, Pulitzer Prize-Winning story.<sup>80</sup>

146. The journalist had been seeking drug shipping sales data since August 8, 2016, when the Charleston Gazette-Mail Newspaper sought access to certain limited ARCOS data. However, “[t]he wholesalers and their lawyers fought to keep the sales numbers secret in previous court actions brought by the newspaper.”<sup>81</sup> But, finally, “[t]he Gazette-Mail obtained previously confidential drug shipping sales records, . . . [which] disclose the number of pills sold to every pharmacy in the state.”<sup>82</sup>

---

<sup>80</sup> Eric Eyre of *Charleston Gazette-Mail*, Charleston, WV, The 2017 Pulitzer Prize Winner in Investigative Reporting, available at <http://www.pulitzer.org/winners/eric-eyre> (last visited July 3, 2017).

<sup>81</sup> Eric Eyre, Drug firms poured 780M painkillers into WV amid rise of overdoses, Charleston Gazette-Mail, December 17, 2016, available at <http://www.wvgazettemail.com/news-health/20161217/drug-firms-poured-780m-painkillers-into-wv-amid-rise-of-overdoses> (last visited July 3, 2017).

<sup>82</sup> *Id.*

147. With the data in its possession, on December 17, 2016, the Gazette-Mail published its shocking analysis of the data.<sup>83</sup> The Gazette-Mail made the following statements, based on the limited West Virginia ARCOS data in its possession about the Defendants conduct in West Virginia:

- “In six years, drug wholesalers showered the state with 780 million hydrocodone and oxycodone pills, while 1,728 West Virginians fatally overdosed on those two painkillers.”<sup>84</sup>
- “While the death toll climbed, drug wholesalers continued to ship massive quantities of pain pills.”<sup>85</sup>
- The quantity of opioids delivered during this period “amount to 433 pain pills for every man, woman and child in West Virginia.”<sup>86</sup>
- “The nation’s three largest prescription drug wholesalers — McKesson Corp., Cardinal Health and AmerisourceBergen Drug Co. — supplied more than half of all pain pills statewide.”<sup>87</sup>
- “For more than a decade, the same distributors disregarded rules to report suspicious orders for controlled substances in West Virginia to the state Board of Pharmacy, the Gazette-Mail found.”<sup>88</sup>
- “Year after year, the drug companies also shipped pain pills in increasing stronger formulations, DEA data shows.”<sup>89</sup>

---

<sup>83</sup> *Id.*

<sup>84</sup> *Id.*

<sup>85</sup> *Id.*

<sup>86</sup> *Id.*

<sup>87</sup> *Id.*

<sup>88</sup> *Id.*

<sup>89</sup> *Id.*

148. Given the Defendant Wholesale Distributors' efforts to mislead the public and conceal its unlawful conduct, as alleged above, Plaintiffs did not have any reason to know of the Defendant Wholesale Distributors' unlawful conduct or their role in creating the opioid nuisance.

149. Plaintiffs were relieved of any duty to investigate because it reasonably and justifiably relied on Defendants to fulfill their reporting requirements and comply with the law. Plaintiffs did not discover and could not have discovered, despite all due diligence, the schemes alleged herein. The conduct revealed by the Gazette-Mail concerned only West Virginia counties (with regard to the Charleston Gazette-Mail publication) or a single distributor (with regard to the DOJ fine against McKesson).

150. Plaintiffs' claims were equitably tolled until Plaintiffs discovered Defendants' conduct shortly before the filing of the Complaint. Defendants are further equitably estopped by their own actions, including their fraudulent concealment, from asserting statute of limitations defenses to Plaintiffs' claims.

## V. CAUSES OF ACTION

### COUNT I PUBLIC NUISANCE ILLINOIS COMMON LAW

151. Plaintiffs incorporate by reference all other paragraphs of this Complaint as if fully set forth here, and further allege as follows.

152. This Count for common law public nuisance is brought by the People of Jersey County and the County of Jersey.

153. Each Defendant is liable for public nuisance because its conduct at issue has caused an unreasonable and substantial interference with a right common to the general public, which is the proximate cause of Plaintiffs' injury.

154. By causing dangerously addictive drugs to flood the community, and to be diverted for illicit purposes, each Defendant has injuriously affected rights common to the general public, specifically including the rights of the people of Jersey County to public health, public safety, public peace, public comfort, and public convenience. The public nuisance caused by Defendants' diversion of dangerous drugs has caused substantial annoyance, inconvenience, and injury to the public.

155. By selling dangerously addictive opioid drugs diverted from a legitimate medical, scientific, or industrial purpose, Defendants have committed a course of conduct that injuriously affects the safety, health, and morals of the People of Jersey County.

156. By failing to maintain a closed system that guards against diversion of dangerously addictive drugs for illicit purposes, Defendants injuriously affected the safety, health and morals of the People of Jersey County.

157. The residents of Jersey County have a common right to be free from conduct that creates an unreasonable jeopardy to the public health, welfare and safety, and to be free from conduct that creates a disturbance and reasonable apprehension of danger to person and property. Specifically, widespread distribution of prescription opioids for illicit purposes jeopardizes these common rights, and the illegal widespread distribution of prescription opioids would not be possible but for the unlawful and intentional acts, or failures to act, by Defendants.

158. Defendants intentionally, unlawfully, and recklessly distribute and sell prescription opioids that Defendants know, or reasonably should know, will be diverted, causing widespread distribution of prescription opioids in and/or to Jersey County illegally, resulting in addiction and abuse, an elevated level of crime, death and injuries to Jersey County residents, a higher level of

fear, discomfort and inconvenience to the residents of Jersey County, and direct costs to Jersey County itself.

159. Defendants have unlawfully and/or intentionally caused and permitted dangerous drugs under their control to be diverted such as to injure the County and its residents.

160. Defendants have unlawfully and/or intentionally distributed opioids without maintaining effective controls against diversion. Such conduct was illegal. Defendants violated the federal and Illinois Controlled Substances Acts. Defendants' failures to maintain effective controls against diversion include Defendants' failures to effectively monitor for suspicious orders, report suspicious orders, and/or stop shipment of suspicious orders.

161. Defendants have caused a substantial and unreasonable interference with the public health, safety, welfare, peace, comfort and convenience, and ability to be free from disturbance and reasonable apprehension of danger to person or property. Moreover, when an enterprise is regulated by state or federal law, as is the case here, the substantial and unreasonable interference element of a public nuisance claim can be met by a showing that Defendants violated applicable statutes or regulations or that Defendants were otherwise negligent in carrying out the enterprise. *Gilmore v. Stanmar, Inc.*, 633 N.E.2d 985, 993 (Ill. 1994). Here, Defendants are not in compliance with applicable law or are otherwise negligent in carrying out their respective enterprises.

162. Defendants' conduct in illegally distributing and selling prescription opioids where Defendants know, or reasonably should know, such opioids will be diverted and possessed and/or used illegally in Jersey County is of a continuing nature and has produced a significant effect upon the public's rights, including the public's right to health and safety.

163. A violation of any rule or law controlling the distribution of a drug of abuse in Jersey County and the State of Illinois is a public nuisance.

164. Defendants' distribution of opioids while failing to maintain effective controls against diversion was proscribed by statute and regulation.

165. Defendants' ongoing conduct produces an ongoing nuisance, as the prescription opioids that they allow and/or cause to be illegally distributed and possessed in Jersey County will be diverted, leading to abuse, addiction, crime, and public health costs.

166. As a result of the continued use and addiction caused by these illegally distributed opioids, the public will continue to fear for its health, safety and welfare, and will be subjected to conduct that creates a disturbance to person and property.

167. Defendants know, and/or reasonably should know, that their conduct will have an ongoing detrimental effect upon the public health, safety and welfare, and the public's ability to be free from disturbance and reasonable apprehension of danger to person and property.

168. Defendants know, or reasonably should know, that their conduct causes an unreasonable invasion of the public right to health, safety and welfare and the public's ability to be free from disturbance and reasonable apprehension of danger to person and property.

169. Defendants are aware, and at a bare minimum certainly should be aware, of the unreasonable interference that their conduct has caused in Jersey County. Defendants are in the business of distributing prescription drugs, including opioids, which are specifically known to Defendants to be dangerous according to federal and Illinois law. *See, e.g.*, 21 U.S.C.A. § 812 (b)(2); 720 ILCS 570/205.

170. Defendants' conduct in marketing, distributing, and selling prescription opioids which the Defendants know, or reasonably should know, will likely be diverted for non-legitimate, non-medical use, creates a strong likelihood that these illegal distributions of opioids will cause death and injuries to Jersey County residents and otherwise significantly and unreasonably

interfere with public health, safety and welfare, and with the public's right to be free from disturbance and reasonable apprehension of danger to person and property.

171. It is, or should be, reasonably foreseeable to Defendants that their conduct will cause deaths and injuries to Jersey County residents, and will otherwise significantly and unreasonably interfere with public health, safety and welfare, and with the public's right to be free from disturbance and reasonable apprehension of danger to person and property.

172. The prevalence and availability of diverted prescription opioids in the hands of irresponsible persons and persons with criminal purposes in Jersey County not only causes deaths and injuries, but also creates a palpable climate of fear among Jersey County residents where opioid diversion, abuse, and addiction are prevalent and where they tend to be used frequently.

173. Defendants' conduct makes it easier for persons to divert prescription opioids, constituting a dangerous threat to the public.

174. Defendants' actions were, at the least, a substantial factor in opioids becoming widely available and widely used for non-medical purposes. Because of Defendants' unique position within the closed system of opioid distribution, without Defendants' actions, opioid use would not have become so widespread, and the enormous public health hazard of prescription opioid and heroin overuse, abuse, and addiction that now exists would have been averted.

175. The presence of diverted prescription opioids in Jersey County, and the consequence of prescription opioids having been diverted in Jersey County, proximately results in significant costs to the County in order to enforce the law, equip its police force, respond to emergencies, and treat the victims of opioid abuse and addiction.

176. Stemming the flow of illegally distributed prescription opioids, and abating the nuisance caused by the illegal flow of opioids, will help to alleviate this problem, save lives, prevent injuries and make Jersey County a safer place to live.

177. Defendants' conduct is a direct and proximate cause of deaths and injuries to Jersey County residents, costs borne by Jersey County, and a significant and unreasonable interference with public health, safety and welfare, and with the public's right to be free from disturbance and reasonable apprehension of danger to person and property.

178. Defendants' conduct constitutes a public nuisance and, if unabated, will continue to threaten the health, safety and welfare of the County's residents, creating an atmosphere of fear and addiction that tears at the residents' sense of well-being and security. Jersey County has a clearly ascertainable right to abate conduct that perpetuates this nuisance.

179. Defendants' actions created and expanded the abuse of opioids, which are dangerously addictive, and the ensuing associated plague of prescription opioid and heroin addiction. Defendants knew the dangers to public health and safety that diversion of opioids would create in Jersey County, however, Defendants intentionally and/or unlawfully failed to maintain effective controls against diversion through proper monitoring, reporting and refusal to fill suspicious orders of opioids. Defendants intentionally and/or unlawfully distributed opioids without reporting, and without refusing to fill, suspicious orders or taking other measures to maintain effective controls against diversion. Defendants intentionally and/or unlawfully continued to ship and failed to halt suspicious orders of opioids. Such actions were inherently dangerous.

180. Defendants knew the prescription opioids have a high likelihood of being diverted. It was foreseeable to Defendants that where Defendants distributed prescription opioids without

maintaining effective controls against diversion, including monitoring, reporting, and refusing shipment of suspicious orders, that the opioids would be diverted, and create an opioid abuse nuisance in Jersey County.

181. Defendants acted recklessly, negligently and/or carelessly, in breach of their duties to maintain effective controls against diversion, thereby creating an unreasonable risk of harm.

182. Defendants acted with actual malice because Defendants acted with a conscious disregard for the rights and safety of other persons, and said actions have a great probability of causing substantial harm. Defendants acted willfully, and with such gross negligence as to indicate a wanton disregard of the rights of others.

183. As a direct and proximate result of Defendants' conduct, the County has suffered actual injury and damages including, but not limited to, significant increased expenses for police, emergency, ambulance services, health, prosecution, corrections and other services. While the County normally has some expenses related to these services, the expenses have been significantly increased as a direct and proximate result of Defendants' conduct, and thus constitute specific and special injuries. The increased expenditures have been a necessary means to respond to issues created by unlawful opioid prescription drugs in the County, but much greater expenditures are needed to abate the serious problems caused by the opioid epidemic.

184. The County has sustained specific and special injuries because its damages include, *inter alia*, health services and law enforcement expenditures, and include without limitation costs sustained by the County Sheriff and State's Attorney offices, costs sustained by the County medical examiners and crime labs, Health and Human Services costs, costs sustained by the County payments for health services, including *inter alia* hospital and ambulance operations, costs related to opioid addiction treatment and overdose prevention, and payments by governmental

payor programs, such as employee health insurance. Thus, Jersey County seeks recovery for its own harm.

185. The County further seeks to abate in the future this nuisance created by the Defendants' unreasonable, unlawful, intentional, ongoing, continuing, and persistent interference with a right common to the public. Such abatement is feasible here and can be accomplished by providing financial resources to the County to combat the problems arising from unlawfully diverted opioids.

186. The public nuisance created by Defendants' actions is substantial and unreasonable – it has caused and continues to cause significant harm to the community, and the harm inflicted outweighs any offsetting benefit. The staggering rates of prescription opioid abuse and heroin use resulting from Defendants' abdication of their gate-keeping duties has caused harm to the entire community that includes, but is not limited to:

- a. The high rates of use have led to unnecessary opioid abuse, addiction, overdose, injuries, and deaths.
- b. Nor have children escaped the opioid epidemic unscathed. Easy access to prescription opioids has made opioids a recreational drug of choice among Illinois teenagers; opioid use among teenagers is only outpaced by marijuana use. Even infants have been born addicted to opioids due to prenatal exposure, causing severe withdrawal symptoms and lasting developmental impacts.
- c. Even those County residents who have never taken opioids have suffered from the public nuisance arising from Defendants' abdication of their gate-keeper duties. Many have endured both the emotional and financial costs of caring for loved ones addicted to or injured by opioids, and the loss of companionship, wages, or other support from

family members who have used, abused, become addicted to, overdosed on, or been killed by opioids.

- d. The opioid epidemic has increased health care costs.
- e. Employers have lost the value of productive and healthy employees.
- f. Defendants' failure to maintain effective controls against diversion of dangerously addictive prescription opioids for non-medical use and abuses has created an abundance of drugs available for criminal use and fueled a new wave of addiction, abuse, and injury.
- g. Defendants' dereliction of duties resulted in a diverted supply of narcotics to sell, and the ensuing demand of addicts to buy them. Increased supply, due to Defendants' conduct, led to more addiction, with many addicts turning from prescription opioids to heroin. People addicted to opioids frequently require increasing levels of opioids, and many turned to heroin as a foreseeable result.
- h. The diversion of opioids into the secondary, criminal market and the increase in the number of individuals who abuse or are addicted to opioids has increased the demands on health care services and law enforcement in the County.
- i. The categories of damages sustained by Jersey County include opioid-related costs and burdens placed upon first responders, whose resources and expertise are necessary to keep our community safe. The resources of *inter alia* emergency responders, police, medical, and ambulance services have been drained, over and above typical municipal community needs, as a result of the opioid epidemic in this County.

- j. The significant unreasonable interference with the public rights caused by Defendants' conduct has taxed the human, medical, public health, law enforcement, and financial resources of Jersey County.
- k. Defendants' interference with the comfortable enjoyment of life in Jersey County is unreasonable because there is little social utility to opioid diversion and abuse, and any potential value is outweighed by the gravity of the harm inflicted by Defendants' actions.

*Prayer for relief.* WHEREFORE, the Plaintiffs, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, respectfully request that this Court award all legal and equitable relief as allowed by law including:

- a. Award judgment in their favor and against Defendants on Count I of the Complaint;
- b. Award Plaintiffs such temporary and preliminary injunctive and ancillary relief as may be necessary to avert the likelihood of further harm and injury to Plaintiffs during the pendency of this action and to preserve the possibility of effective final relief;
- c. Permanently enjoin Defendants from further diversion of dangerous opioids;
- d. Compel Defendants to pay restitution of any money acquired as a result of Defendants' methods, acts, or practices;
- e. Compel Defendants to disgorge any and all ill-gotten profits;
- f. An order compelling Defendants to abate the public nuisance caused by their diversion of opioids into non-medical, non-scientific, and non-industrial uses;
- g. Allocate monetary damages attributable to each Defendant to compensate the Plaintiffs for the costs that the County bears, including past and future damages, as a

- result of the public nuisance;
- h. Allocate punitive damages attributable to each Defendant;
  - i. Compel Defendants to pay the costs of the suit, including costs of Plaintiffs' investigation, costs incurred as a result of prosecuting this case, and attorneys' fees;
  - j. Award pre- and post-judgment interest in an amount as allowed by law; and
  - k. Award Plaintiffs such other additional relief as the Court may determine to be just and proper.

**COUNT II**  
**RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS ACT (RICO)**  
**18 U.S.C. §§ 1961, et seq.**

187. Plaintiffs incorporate by reference all other paragraphs of this Complaint as if fully set forth here, and further allege as follows.

188. This Count is brought by the People of Jersey County and the County of Jersey, for civil relief only.

189. Each Defendant is associated with an enterprise which affects interstate commerce for purposes which include the illegal distribution of opioids. As explained herein, each Defendant Wholesale Distributor conducted or participated in the enterprise's affairs through commission of criminal offenses which constitute a pattern of racketeering activity.

190. Defendant corporations are "persons" within the meaning of 18 U.S.C. § 1961(3) which conducted the affairs of an enterprise through a pattern of racketeering activity, in violation of 18 U.S.C. § 1962.

191. The County was injured in its business or property as a result of each Defendant's wrongful conduct and is a "person" who can bring an action for violation of section 1962, as that term is defined in 18 U.S.C. § 1961(3). "Any person injured in his business or property by reason of a violation of section 1962 of this chapter may sue therefor in any appropriate United States

district court and shall recover threefold the damages he sustains and the cost of the suit, including a reasonable attorney's fee...." 18 U.S.C. § 1964.

**A. The Opioids Diversion Enterprise.**

192. Each Defendant formed an association-in-fact enterprise ("Opioids Diversion Enterprise"), and participated in the affairs of this enterprise when distributing highly dangerous, addictive opioid drugs in Jersey County. Each Defendant's Opioids Diversion Enterprise consists of (a) each Defendant, including its employees, co-Defendant subsidiaries, and agents; and (b) each Defendant's retail pharmacies which placed orders for vast quantities of opioids. Indeed, the Defendants could not have diverted opioids without the participation of retail pharmacies. The events described herein required retail pharmacies to place orders for these vast quantities of opioids.

193. Each Defendant and its respective pharmacy customers participated in the conduct of the Opioids Diversion Enterprise, sharing the common purpose of profiting from the sale of opioids, through a pattern of racketeering activity, which includes multiple violations of the Illinois Controlled Substances Act, constituting a felony, and multiple instances of federal mail and wire fraud.

194. Each Defendant's Opioids Diversion Enterprise is an ongoing and continuing business organization that created and maintained systematic links for a common purpose: to profit from the sale of opioid prescription pills. Each Defendant conducted this enterprise notwithstanding that its failure to abide by mandatory checks and balances constituted unlawful diversion of a dangerous controlled substance.

195. The system is structured such that wholesalers and pharmacies see greater profits at higher volumes. As a result, these companies are financially discouraged from undertaking efforts to combat opioid abuse. Wholesale Distributors acquire pharmaceuticals, including opioids,

from manufacturers at an established wholesale acquisition cost (“WAC”). Discounts and rebates may be offered by the manufacturers based on, *inter alia*, market share and volume. Thus, the Defendant Wholesale Distributors are incentivized to order greater amounts so that they can decrease the cost per pill. The Defendant Wholesale Distributors used the decreased cost per pill to increase their market share (and thus, profits), by offering more competitive prices, or they maintained their prices and pocketed the difference as additional profit. Either way, increased sales volumes result in increased profits. At every turn, each Defendant maximized its profits through discounts and rebates by ordering and selling more opioids.<sup>90</sup>

196. As described above and expressly incorporated herein, the Defendant Wholesale Distributors: (a) were placed on notice by the DEA, and were the subject of repeated DEA enforcement actions; and (b) misrepresented their compliance with their legal obligations to maintain a closed system.

197. Each Defendant’s Opioid Diversion Enterprise has caused opioids to be abused throughout Jersey County, with an ongoing cascade of human suffering and death that continues to consume the resources of the County’s health and human services, health care, and law enforcement systems.

198. Each Defendant and its respective retail pharmacy customers were willing participants in the Opioids Diversion Enterprise, had a common purpose and interest in the object of the scheme, and functioned within a structure designed to effectuate the Enterprise’s purpose.

---

<sup>90</sup> “Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain,” The Kaiser Family Foundation, March 2005.

## **B. Conduct of the Opioids Diversion Enterprise**

199. To accomplish the common purpose of profiting from the sale of opioid prescription pills, each Defendant's Opioids Diversion Enterprise periodically and systematically misrepresented – either affirmatively or through half-truths and omissions – to the general public, the County, Illinois consumers, and the Illinois Department of Financial and Professional Regulation, that it was fulfilling the requirements of its Illinois wholesale distributor license when, in fact, the duty to maintain effective controls to prevent diversion for non-medical purposes was being ignored in pursuit of ever increasing profits.

200. The persons engaged in each Defendant's Opioids Diversion Enterprise are systematically linked through contractual relationships, financial ties, and continuing coordination of activities. Typically, this communication occurred, and continues to occur, through the use of the wires and mail in which each Defendant and its respective retail pharmacy customers communicate to facilitate the prescription opioid orders.

201. Each Defendant's Opioids Diversion Enterprise functions as a continuing unit for the purposes of profiting from the sale of opioid prescription drugs.

202. At all relevant times, the retail pharmacy customers were aware of Defendants' conduct, were knowing and willing participants in that conduct, and reaped benefits from that conduct.

203. The sheer volume of prescription opioids flooding out of the doors of the Defendant Wholesale Distributors and into communities across the country, including Jersey County, shocks the conscience and required each Defendant Wholesale Distributor to take appropriate action, such as investigating and reporting the orders as suspicious. Given their place in the supply chain, the Defendant Wholesale Distributors are uniquely situated to identify suspicious transactions. However, determined to increase their revenues, each of the Defendant Wholesale Distributors

willfully ignored obvious warning signs concerning suspicious orders. It would be virtually impossible for all of the orders to be legitimate, as there was no medical-need correlation justifying the skyrocketing orders for these addictive drugs.

204. For all times relevant to this Complaint, each Defendant exerted control over its Opioids Diversion Enterprise and participated in the operation and management of the affairs of the Opioids Diversion Enterprise, directly or indirectly, in the following ways:

- a. Defendants obtained a license from the Illinois Department of Financial and Professional Regulation but, contrary to the requirements of Illinois law, including federal laws incorporated by reference into Illinois law, Defendants failed to take necessary action to maintain effective controls against diversion of dangerously addictive prescription opioids, and in dereliction of non-delegable duties, sold opioid pills to their retail pharmacy customers notwithstanding that the increase and quantum of addictive drug orders raised serious red flags regarding the drugs' unlawful, non-medical use;
- b. Defendants misrepresented their compliance with their legal obligations, making false assurances that their distribution complied with the law, including without limitation the requirements of an Illinois distributor license, when, in truth, Defendants sold all the opioids they could, for profit, and in violation of their legal duties to guard against diversion of prescription opioids for illicit purposes;
- c. Defendants refused to heed the DEA's warnings and continued to sell opioids and fill suspicious orders which were likely to be diverted;
- d. Defendants refused to abide by the terms of DEA enforcement actions and settlements, continuing to sell opioids to fill suspicious orders;

- e. Defendants did not monitor, detect, investigate, refuse to fill, and report suspicious orders to the DEA as required under the terms of their licenses and applicable law;
- f. Defendants intentionally and/or unlawfully sold the opioids unlawfully, purely for profit and without regard to the opioid plague, notwithstanding Defendants' knowledge that substantial foreseeable harm would occur; and,
- g. Defendants only succeeded in these opioid sales by using wire and mail to communicate with the retail pharmacies.

205. The retail pharmacies participated in each Defendant's Opioid Diversion Enterprise by employing mail and wire to send orders of opioids to Defendants and to buy opioids from Defendants. The retail pharmacies also participated in each Defendant's Opioid Diversion Enterprise by engaging with Defendants in violation of the Illinois Controlled Substances Act, Chapter 720, Act 570, as described herein.

206. The scheme devised and implemented by each Defendant, as well as other members of each Defendant's Opioids Diversion Enterprise, amounted to a common course of conduct intended to profit from Opioid sales.

### **C. Pattern of Racketeering Activity**

207. Each Defendant conducted and participated in the conduct of the affairs of each Defendant's Opioids Marketing Enterprise through a pattern of racketeering activity, which violates 18 U.S.C. § 1962(c).

208. Regardless of any licenses or registrations held by Defendants to distribute dangerous and harmful drugs, their conduct was neither "lawful" nor "authorized." Defendants engaged in a fraudulent and unlawful course of conduct constituting a pattern of racketeering activity.

209. The pattern of racketeering activity alleged herein and each Defendant's Opioids Diversion Enterprise are separate and distinct from each other. Likewise, each Defendant is distinct from its respective Opioids Diversion Enterprise.

210. The pattern of racketeering activity alleged herein is continuing as of the date of this Complaint and, upon information and belief, will continue into the future unless enjoined by this Court.

211. Many of the precise dates of the Defendants' criminal actions at issue here have been hidden and cannot be alleged without access to Defendants' books and records. Indeed, Defendants' misrepresentations to the public, the Illinois Department of Financial and Professional Regulation, and the DEA, depended on secrecy.

212. Each instance of racketeering activity alleged herein was related, had similar purposes, involved the same or similar participants and methods of commission, and had similar results affecting similar victims, including the County and its citizens. Each Defendant crafted its scheme to ensure its own profits remained high, without regard to the effect such behavior had on the County and its citizens. In designing and implementing their respective schemes, at all times each Defendant was cognizant of the fact that those in the distribution chain and the Illinois Department of Financial and Professional Regulation and DEA, *inter alia*, rely on the integrity of the wholesale distributors to maintain a closed system and to protect against the non-medical uses of these dangerously addictive opioid drugs.

213. Each Defendant knowingly engaged in, attempted to engage in, conspired to engage in, or solicited another person to engage in racketeering activity, including the distribution of dangerous and harmful drugs to persons, including minors, in violation of the Illinois Controlled

Substances Act, Chapter 720, Act 570, at retail pharmacies, hospitals, and other health care facilities throughout the County of Jersey.

214. Each Defendant's actions were in violation of Chapter 720, Act 570, of the Illinois Compiled Statutes, and more specifically: 720 ILCS 570/401, which forbids delivery of controlled substances; 720 ILCS 570/401.1, which forbids the trafficking of controlled substances; and, 720 ILCS 570/405 and 720 ILCS 570/405.1, which forbid criminal drug conspiracies.

215. Defendants violated Section 401 of the Illinois Controlled Substances Act, which provides that, “[e]xcept as authorized by this Act, it is unlawful for any person knowingly to manufacture or deliver, or possess with intent to manufacture or deliver, a controlled substance.” 720 ILCS 570/401.

216. Defendants violated Section 401.1 of the Illinois Controlled Substances Act, which provides that, “[e]xcept for purposes as authorized by this Act, any person who knowingly brings or causes to be brought into this State for the purpose of manufacture or delivery or with the intent to manufacture or deliver a controlled substance ... in this or any other state or country is guilty of controlled substance trafficking.” 720 ILCS 570/401.1.

217. Defendants violated Section 405.1 of the Controlled Substances Act, which provides that a person commits criminal drug conspiracy when, with the intent that an offense in Section 401 be committed, it agrees with another to the commission of that offense. 720 ILCS 570/405.1. Defendants also violated Section 405 of the Controlled Substances Act by conspiring to violate Section 401 and thereby obtaining monies greater than \$500. 720 ILCS 570/405. Defendants committed acts in furtherance of such conspiracies.

218. Defendants do not qualify for the “authorized by this Act” exceptions to Controlled Substance Act violations because Defendants did not comply with the mandatory terms of the

licenses issued to them by the Department of Financial and Professional Regulation, or with federal requirements incorporated by reference, as further detailed in this Complaint.

219. Defendants' violations of the Illinois Controlled Substances Act qualify as felonies carrying a prison term in excess of one year, and therefore the violations constitute racketeering activity under 18 U.S.C. § 1961(1)(A).

220. In addition, each Defendant knowingly engaged in, attempted to engage in, conspired to engage in, or solicited another person to engage in racketeering activity, including thousands of separate instances of use of the United States Mail or interstate wire facilities in furtherance of each Defendant's unlawful Opioids Diversion Enterprise. Each of these fraudulent mailings and interstate wire transmissions constitutes racketeering activity and collectively, these violations constitute a pattern of racketeering activity. Each Defendant specifically intended to obtain money by means of false pretenses, representations, and promises, and used the mail and interstate wires for the purpose of executing this scheme; specifically, each Defendant communicated with its respective retail pharmacy customers via wire and used the mail to receive orders and sell drugs unlawfully. Any violation of the mail or wire fraud statutes is defined as "racketeering activity." 18 U.S.C. § 1961(1)(B).

#### **D. Damages**

221. Defendants' violations of law and their pattern of racketeering activity have directly and proximately caused the County and its citizens to be injured in their business or property because the County has paid for costs associated with the opioid epidemic, as described in this Complaint.

222. The County's injuries, and those of her citizens, were proximately caused by Defendants' racketeering activities. But for Defendants' conduct, the County would not have paid

*inter alia* the health services and law enforcement services expenditures required by the plague of drug-addicted residents.

223. The County's injuries, and those of her citizens, were directly caused by Defendants' racketeering activities.

224. The County was most directly harmed, and there is no other Plaintiff better situated to seek a remedy for the economic harms at issue here.

*Prayer for relief.* WHEREFORE, the Plaintiffs, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, respectfully request that this Court award all legal and equitable relief as allowed by law including:

- a. Award judgment in their favor and against Defendants on Count II of the Complaint;
- b. Award Plaintiffs such temporary and preliminary injunctive and ancillary relief as may be necessary to avert the likelihood of further harm and injury to Plaintiffs during the pendency of this action and to preserve the possibility of effective final relief;
- c. Permanently enjoin Defendants from further diversion of dangerous opioids;
- d. Compel Defendants to pay restitution of any money acquired as a result of Defendants' methods, acts, or practices in violation of RICO;
- e. Compel Defendants to disgorge any and all ill-gotten profits;
- f. Allocate monetary damages attributable to each Defendant to compensate the Plaintiffs for the costs that the County bears, including past and future damages, as a result of the Defendants' violations of RICO;
- g. Allocate treble damages attributable to each Defendant;
- h. Compel Defendants to pay the costs of the suit, including costs of Plaintiffs' investigation, costs incurred as a result of prosecuting this case, and attorneys' fees

- (18 U.S.C. §1964(c));
- i. Award civil penalties as allowed by law;
  - j. Award pre- and post-judgment interest in an amount as allowed by law; and
  - k. Award Plaintiffs such other additional relief as the Court may determine to be just and proper.

**COUNT III**  
**NARCOTICS PROFIT FORFEITURE ACT**  
**725 ILCS 175/1 *et seq.***

225. Plaintiffs incorporate by reference all other paragraphs of this Complaint as if fully set forth here, and further allege as follows.

226. This Count is brought by the People of Jersey County and the County of Jersey. This Count is brought pursuant to 725 ILCS 175/7 for civil relief only. Plaintiffs were injured in their business, person, and/or property as a result of each Defendant's wrongful conduct (725 ILCS 175/6(c)), and are persons who can bring an action for civil damages, threefold damages, and attorney fees (725 ILCS 175/3(c)).

227. Defendant corporations are "persons" within the meaning of 725 ILCS 175/3(c), which conducted the affairs of an opioid narcotics racketeering enterprise through a pattern of racketeering activity, in violation of Chapter 725, Act 175, the Illinois Narcotics Profit Forfeiture Act.

**A. The Opioids Diversion Enterprise.**

228. Allegations regarding each Defendant's formation of and participation in each Defendant's Opioids Diversion Enterprise are set out herein, including in Count II, *supra*, which allegations are incorporated as if fully set forth herein.

229. Defendants' Opioids Diversion Enterprise is an association in fact and meets the definition of enterprise in 725 ILCS 175/3(d).

**B. Conduct of the Opioids Diversion Enterprise.**

230. Allegations regarding Defendants' conduct in relation to the Opioids Diversion Enterprise are set out herein, including in Count II, *supra*, which allegations are incorporated as if fully set forth herein.

231. As alleged above in language incorporated herewith by reference, each Defendant has violated the Illinois Controlled Substances Act and the United States Controlled Substances Act, and such conduct is punishable as a felony. Therefore, each Defendant has engaged in narcotics activity, as prohibited by the Narcotics Profit Forfeiture Act, 725 ILCS 175/3(a).

232. Each Defendant receives income knowing such income is derived from the pattern of racketeering activity in which it participated, which is prohibited by the Narcotics Profit Forfeiture Act, 725 ILCS 175/4(a). As more fully described in this Complaint, each Defendant is aware that it has diverted dangerously addictive opioid narcotics into illicit streams of commerce in violation of mandatory, non-delegable duties and requirements for state and federal wholesale drug distribution licenses and registrations. Defendants have received income by distributing dangerous Schedule II substances in violation of state and federal Controlled Substances Acts and associated regulations.

233. As more fully described in this Complaint, in addition to said receipt of income, each Defendant uses or invests all or part of the income, or proceeds of such income, to establish, acquire, and/or operate an enterprise doing business in the State of Illinois, which is prohibited by the Narcotics Profit Forfeiture Act, 725 ILCS 175/4(b).

234. As more fully described in this Complaint, each Defendant knowingly, through a pattern of narcotics activity, acquires and maintains an interest in or contract of an enterprise which is engaged in, and which activities affect, business in the State of Illinois, which is prohibited by the Narcotics Profit Forfeiture Act, 725 ILCS 175/4(c).

235. As more fully described in this Complaint, each Defendant is associated with an enterprise doing business in the State of Illinois and knowingly conducts or participates in the conduct of such enterprise's affairs through a pattern of narcotics activity in which Defendants participate, as prohibited by the Narcotics Profit Forfeiture Act, 725 ILCS 725/4(d).

**C. Pattern of Racketeering Activity**

236. Allegations regarding Defendants' conduct in relation to the Opioids Diversion Enterprise's pattern of racketeering activity are set out herein, including in Count II, *supra*, which allegations are incorporated as if fully set forth herein. Each Defendant conducted and participated in the conduct of the affairs of each Defendant's Opioids Marketing Enterprise through a pattern of racketeering activity, which violates Chapter 725, Act 175, the Illinois Narcotics Profit Forfeiture Act.

237. As explained herein, each Defendant conducted or participated in the enterprise's affairs through commission of criminal offenses which constitute a pattern of narcotics racketeering activity. 725 ILCS 175/3(b). Each Defendant has committed two or more, and indeed multiple, acts of narcotics activity within 5 years of each other. At least one, and indeed multiple, acts of narcotics activity were committed after the effective date of Act 175. At least one of these acts, and indeed multiple, acts of narcotics activity are punishable as a Class X, 1, or 2 felonies.

**D. Damages**

238. Defendants' violations of law and their pattern of racketeering activity have directly and proximately caused the County and its citizens to be injured in their business or property because the County has paid for costs associated with the opioid epidemic, as described above in language expressly incorporated herein by reference.

239. The County's injuries were proximately caused by Defendants' racketeering activities. But for Defendants' conduct, the County would not have paid *inter alia* the health

services and law enforcement services expenditures required by the plague of drug-addicted residents.

240. The County's injuries were directly caused by Defendants' racketeering activities.

*Prayer for relief.* WHEREFORE, the Plaintiffs, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, respectfully request that this Court award all legal and equitable relief as allowed by law including:

- a. Award judgment in their favor and against Defendants on Count III of the Complaint;
- b. Award Plaintiffs such temporary and preliminary injunctive and ancillary relief as may be necessary to avert the likelihood of further harm and injury to Plaintiffs during the pendency of this action and to preserve the possibility of effective final relief;
- c. Permanently enjoin Defendants from further diversion of dangerous opioids;
- d. Compel Defendants to pay restitution of any money acquired as a result of Defendants' methods, acts, or practices in violation of the Illinois Narcotics Profit Forfeiture Act;
- e. Compel Defendants to disgorge any and all ill-gotten profits;
- f. Allocate monetary damages attributable to each Defendant to compensate the Plaintiffs for the costs that the County bears, including past and future damages, as a result of the Defendants' violations of the Narcotics Profit Forfeiture Act;
- g. Allocate treble damages attributable to each Defendant (725 ILCS 175/6(c));
- h. Compel Defendants to pay the costs of the suit, including costs of Plaintiffs' investigation, costs incurred as a result of prosecuting this case, and attorneys' fees (725 ILCS 175/6(c));
- i. Award pre- and post-judgment interest in an amount as allowed by law; and,

j. Award Plaintiffs such other additional relief as the Court may determine to be just and proper.

**COUNT IV**  
**CONSUMER FRAUD AND DECEPTIVE BUSINESS PRACTICES ACT**  
**815 ILCS 505/1 *et seq***

241. Plaintiffs incorporate by reference all other paragraphs of this Complaint as if fully set forth here, and further allege as follows.

242. This Count is brought by THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County. Benjamin L. Goetten, the State's Attorney of Jersey County, has reason to believe that each of the Defendants named herein is in violation of the Illinois Consumer Fraud and Deceptive Business Practices Act ("Fraud Act"), 815 ILCS 505/1 *et seq.*, and further that this action is in the public interest of the Plaintiffs, The People of the State of Illinois, The People of Jersey County, and County of Jersey. Count IV is brought pursuant to Section 7 of the Fraud Act, 815 ILCS 505/7. The Fraud Act may be enforced through this Court through pendent jurisdiction pursuant to 28 U.S.C. § 1367.

243. Plaintiffs have met the heightened particularity pleading standard of Rule 9(b) to bring this Fraud Act claim. Similarly, Plaintiffs will diligently amend these pleadings when necessary facts become available.

244. As evidenced by the conduct detailed above, Defendants have violated Section 2 of the Fraud Act, 815 ILCS 505/2, by engaging in one or more of the following deceptive methods, acts and practices:

a. The use or employment of any deception, fraud, false pretense, false promise, misrepresentation or the concealment, suppression or omission of any material fact,

- with intent that others rely upon the concealment, suppression or omission of such material fact; and/or
- b. The use or employment of deceptive trade practices enumerated under Section 2 of the Uniform Deceptive Trade Practices Act, 815 ILCS 510/2, including:
- i. Causing likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of goods or services;
  - ii. Representing that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities that they do not have or that a person has a sponsorship, approval, status, affiliation, or connection that he or she does not have; and/or
  - iii. Engaging in other conduct which similarly creates a likelihood of confusion or misunderstanding.

245. As also described in greater detail above, Defendants' deceptive methods, acts or practices specifically include, but are not necessarily limited to, the following:

- a. The method, act or practice of not monitoring for suspicious orders of prescription opioids;
- b. The method, act or practice of not detecting suspicious orders of prescription opioids;
- c. The method, act or practice of not investigating suspicious orders of prescription opioids;
- d. The method, act or practice of filling, or failing to refuse fulfillment of, suspicious orders of prescription opioids;
- e. The method, act or practice of not reporting suspicious orders of prescription opioids;
- f. The method, act or practice of rewarding increases in prescription opioid sales; and/or
- g. The method, act or practice of falsely misrepresenting to the public that Defendants were complying with their legal obligations.

246. All of Defendants' deceptive methods, acts or practices were conducted with the intent on Defendants' part that persons in the State of Illinois and Jersey County, the Department of Financial and Professional Regulation, and Jersey County itself rely on the deception.

247. All of Defendants' deceptive methods, acts or practices occurred in the course of conduct involving trade or commerce.

248. All of Defendants' deceptive methods, acts or practices harmed or damaged Plaintiffs.

249. Some or all of Defendants' violations of the Fraud Act were committed with the intent to defraud, and many or all violations were continuous in nature.

250. Many of Defendants' violations of the Fraud Act were committed against persons 65 years of age or older.

251. Absent injunctive relief by this Court, Defendants are likely to continue to harm and injure Plaintiffs, reap unjust enrichment, and harm the public interest.

252. Section 7 of the Fraud Act, 815 ILCS 505/7, empowers this Court to grant injunctive and such other relief as it may find appropriate to halt and redress violations of the Fraud Act, including restitution, civil penalties, and costs.

*Prayer for relief.* WHEREFORE, the Plaintiffs, THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, seek all legal and equitable relief as allowed by law, and respectfully request that this Court:

- a. Award judgment in their favor and against Defendants on Count IV of the Complaint;
- b. Award Plaintiffs such temporary and preliminary injunctive and ancillary relief as may be necessary to avert the likelihood of further harm and injury to Plaintiffs during the

- pendency of this action and to preserve the possibility of effective final relief;
- c. Permanently enjoin Defendants from violating the Fraud Act;
  - d. Compel Defendants to pay restitution of any money acquired as a result of Defendants' methods, acts, or practices in violation of the Fraud Act;
  - e. Compel Defendants to disgorge any and all ill-gotten profits;
  - f. Assess a civil penalty in the amount of Fifty Thousand Dollars (\$50,000) per violation of the Fraud Act found by the Court to have been committed by Defendants with the intent to defraud; if the Court finds Defendants have engaged in methods, acts, or practices declared unlawful by the Fraud Act without the intent to defraud, then assessing a statutory civil penalty of Fifty Thousand Dollars (\$50,000), all as provided in Section 7(b) of the Fraud Act, 815 ILCS 505/7(b);
  - g. Assess an additional civil penalty, not to exceed Ten Thousand Dollars (\$10,000), per violation of the Fraud Act found by the Court to have been committed by Defendants against a person 65 years of age or older, as provided in Section 7(c) of the Fraud Act, 815 ILCS 505/7(c);
  - h. Compel Defendants to pay the costs of the suit, including costs of Plaintiffs' investigation, costs incurred as a result of prosecuting this case, and attorneys' fees;
  - i. Award pre- and post-judgment interest in an amount as allowed by law; and,
  - j. Award Plaintiffs such other additional relief as the Court may determine to be just and proper.

**COUNT V**  
**UNIFORM DECEPTIVE TRADE PRACTICES ACT**  
**815 ILCS 510/1 *et seq.***

253. Plaintiffs incorporate by reference all other paragraphs of this Complaint as if fully set forth here, and further allege as follows.

254. This Count is brought by THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County. Plaintiffs have standing under the Uniform Deceptive Trade Practices Act ("UDTPA"), 815 ILCS 510/1 *et seq.*, as they are "government[s] or governmental subdivision[s]" and are therefore "person[s]" under the definitions of the UDTPA. *See* 815 ILCS 510/1(5). Benjamin L. Goetten, the State's Attorney of Jersey County and legal representative of Jersey County, is empowered to bring Count V of this action on behalf of the Plaintiffs, The People of the State of Illinois, The People of Jersey County, and County of Jersey, pursuant to the powers and duties vested to him by 55 ILCS 5/3-9005(a) and the doctrine of *parens patriae*. Additionally, the UDTPA may be enforced through this Court through pendent jurisdiction pursuant to 28 U.S.C.A. § 1367.

255. As evidenced by the conduct detailed above, Defendants have violated Section 2 of the UDTPA, 815 ILCS 510/2, by engaging in one or more of the following deceptive trade practices:

- a. Causing likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of goods or services;
- b. Representing that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities that they do not have or that a person has a sponsorship, approval, status, affiliation, or connection that he or she does not have; and/or
- c. Engaging in other conduct which similarly creates a likelihood of confusion or misunderstanding.

256. As also described in greater detail above, Defendants' deceptive trade practices specifically include, but are not necessarily limited to, the following:

- a. The practice of not monitoring for suspicious orders of prescription opioids;
- b. The practice of not detecting suspicious orders of prescription opioids;
- c. The practice of not investigating suspicious orders of prescription opioids;
- d. The practice of filling, or failing to refuse fulfillment of, suspicious orders of prescription opioids;
- e. The practice of not reporting suspicious orders of prescription opioids;
- f. The practice of rewarding increases in prescription opioid sales; and/or
- g. The practice of falsely misrepresenting to the public that Defendants were complying with their legal obligations.

257. Plaintiffs have been damaged, and are likely to be further damaged in the future, by the deceptive trade practices described herein.

258. Defendants egregiously and willfully engaged in the deceptive trade practices described herein.

259. Section 3 of the UDTPA, 815 ILCS 510/3, empowers this Court to grant injunctive relief upon terms it considers reasonable, as well as costs and attorneys' fees against Defendants if the Court finds that Defendants willfully engaged in a deceptive trade practice.

*Prayer for relief.* WHEREFORE, the Plaintiffs, THE PEOPLE OF THE STATE OF ILLINOIS, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, respectfully request that this Court:

- a. Award judgment in their favor and against Defendants on Count V of the Complaint;
- b. Award Plaintiffs such temporary and preliminary injunctive and ancillary relief as may

be necessary to avert the likelihood of further harm and injury to Plaintiffs during the pendency of this action and to preserve the possibility of effective final relief;

- c. Permanently enjoin Defendants from violating the UDTPA;
- d. Compel Defendants to pay the costs of the suit, including attorneys' fees;
- e. Award pre- and post-judgment interest in an amount as allowed by law; and,
- f. Award Plaintiffs such other additional relief as the Court may determine to be just and proper.

**COUNT VI  
NEGLIGENCE  
ILLINOIS COMMON LAW**

260. Plaintiffs incorporate by reference all other paragraphs of this Complaint as if fully set forth here, and further allege as follows.

261. This Count for common law negligence is brought by the People of Jersey County and the County of Jersey.

262. "To state a cause of action for negligence, a complaint must allege facts that establish the existence of a duty of care owed by the defendant to the plaintiff, a breach of that duty, and an injury proximately caused by that breach." *Simpkins v. CSX Transp., Inc.*, 965 N.E.2d 1092, 1096 (Ill. 2012) (quot. & cit. om.). All such essential elements exist here.

263. Each Defendant had an obligation to exercise due care in distributing highly dangerous opioid drugs in Jersey County.

264. If a course of action creates a foreseeable risk of injury, the individual engaged in that course of action has a duty to protect others from such injury. *Simpkins*, 965 N.E.2d at 1097. Each Defendant owed a duty to Jersey County, and to the public health and safety in Jersey County, because the injury was foreseeable, and in fact foreseen, by the Defendants.

265. In addition, each Defendant owed a duty to the County because the injury was likely. Each Defendant was required to guard against the injury as a requirement for the licenses each Defendant maintains, and the burden of guarding against the injury was voluntarily assumed and not unduly onerous. The burden of guarding against the injury is properly placed upon each Defendant, and indeed, federal and state licensing and registration requirements required that each Defendant guard against the diversion of dangerously addictive opioids for illicit purposes.

266. Reasonably prudent wholesale drug distributors would have anticipated that the scourge of opioid addiction would wreak havoc on communities. As explained above, the system whereby wholesale distributors are the gatekeepers between manufacturers and pharmacies exists *for the purpose* of controlling dangerous substances such as opioids. Defendants were repeatedly warned by law enforcement. The escalating amounts of addictive drugs flowing through Defendants' businesses, and the sheer volume of these prescription opioids, further alerted Defendants that addiction was fueling increased consumption and that legitimate medical purposes were not being served.

267. As described above in language expressly incorporated herein, Defendants breached their duties to exercise due care in the business of wholesale distribution of dangerous opioids, which are Schedule II Controlled Substances, by filling highly suspicious orders time and time again. Because the very purpose of these duties was to prevent the resulting harm – diversion of highly addictive drugs for non-medical purposes – the causal connection between Defendants' breach of duties and the ensuing harm was entirely foreseeable.

268. In addition, Defendants' violations of public safety laws is *prima facie* evidence of negligence. Each Defendant had a duty under, *inter alia*, these laws to maintain effective controls against diversion of prescription opioids and to guard against, prevent, and report suspicious orders

of opioids. Defendants' violations of the law constitute negligence per se. Defendants breached mandatory, non-delegable legal duties and did not act reasonably under the circumstances.

269. As described above in language expressly incorporated herein, Defendants' breach of duty caused, bears a causal connection with, and/or proximately resulted in, harm and damages to Jersey County.

270. As described above in language expressly incorporated herein, Defendants breached their duties to maintain effective controls against diversion of dangerously addictive opioids, including violating public safety statutes and regulations requiring that as wholesale drug distributors, Defendants could only distribute these dangerous drugs under a closed system – a system Defendants were responsible for guarding.

271. As described above in language expressly incorporated herein, Defendants' breach of statutory and regulatory duties caused, bears a causal connection with, and proximately resulted in, harm and damages to Jersey County.

272. It was foreseeable that the breach of duty described herein would result in the damages sustained by Jersey County.

273. Defendants acted with actual malice, willfully, and with such gross negligence as to indicate a wanton disregard of the rights of others. Punitive damages are necessary to deter similar conduct in the future.

*Prayer for relief.* WHEREFORE, the Plaintiffs, THE PEOPLE OF JERSEY COUNTY, and COUNTY OF JERSEY, by BENJAMIN L. GOETTEN, the State's Attorney of Jersey County, respectfully request that this Court award all legal and equitable relief as allowed by law including:

- a. Award judgment in their favor and against Defendants on Count VI of the Complaint;
- b. Award Plaintiffs such temporary and preliminary injunctive and ancillary relief as may

- be necessary to avert the likelihood of further harm and injury to Plaintiffs during the pendency of this action and to preserve the possibility of effective final relief;
- c. Permanently enjoin Defendants from further diversion of dangerous opioids;
  - d. Compel Defendants to pay restitution of any money acquired as a result of Defendants' negligent methods, acts, or practices;
  - e. Compel Defendants to disgorge any and all ill-gotten profits;
  - f. Allocate monetary damages attributable to each Defendant to compensate the Plaintiffs for the costs that the County bears, including past and future damages, as a result of Defendants' negligence;
  - g. Allocate punitive damages attributable to each Defendant;
  - h. Compel Defendants to pay the costs of the suit, including costs of Plaintiffs' investigation, costs incurred as a result of prosecuting this case, and attorneys' fees;
  - i. Award pre- and post-judgment interest in an amount as allowed by law; and
  - j. Award Plaintiffs such other additional relief as the Court may determine to be just and proper.

## **VI. CONCLUSION**

274. Defendant Wholesale Distributors had a duty to abide by safety laws and maintain effective controls against diversion of controlled substances under both Illinois and federal law, including a duty to monitor, detect, report, and refuse to fill suspicious orders of prescription opioids. Plaintiffs alleges that the Defendant Wholesale Distributors unlawfully, negligently, and intentionally breached their duties under federal and Illinois law, and that such breaches are a proximate cause of the opioid epidemic plaguing Jersey County. The unlawful, intentional, and negligent conduct by the Defendant Wholesale Distributors has created a hazard to public health and safety in Jersey County and constitutes a public nuisance under Illinois law.

## **VII. AD DAMNUM**

**WHEREFORE**, Plaintiffs, the People of the State of Illinois, the People of Jersey County, the County of Jersey, by Benjamin L. Goetten, the State's Attorney of Jersey County, hereby respectfully request trial by jury and that this Court adjudge and decree that Defendants are liable for creating a public nuisance, enter judgment for the Plaintiffs and against Defendants, award the relief requested in each *prayer for relief* above, and:

1. Enter Judgment in favor of the County in a final order against each of the Defendants;
2. Enjoin the Defendants and their employees, officers, directors, agents, successors, assignees, merged or acquired predecessors, parent or controlling entities, subsidiaries, and all other persons acting in concert or participation with them, from engaging in unlawful sales of prescription opioid pills and ordering temporary, preliminary or permanent injunction;
3. Allocate monetary damages attributable to each Defendant for each Count pled above;
4. Order that Defendants compensate the County for its past and future damages and costs to abate the ongoing public nuisance caused by the opioid epidemic;
5. Impose an award of actual and triple the actual damages the County sustained as a result of each Defendant's violation of the Racketeer Influenced and Corrupt Organizations Act, and any allowable civil penalty;
6. Impose an award of actual and triple the actual damages the County sustained as a result of each Defendant's violation of the Narcotics Profit Forfeiture Act;
7. Order that each Defendant pay restitution;
8. Order that each Defendant disgorge profits;
9. Order that each Defendant is liable for civil penalties under Illinois law;

10. Allocate monetary damages attributable to each Defendant to compensate the County for the expenses and costs that it bears as a result of the public nuisance, including without limitation (A) costs for providing medical care, additional therapeutic, and prescription drug purchases, and other treatments/services for patients suffering from opioid-related addiction or disease, including overdoses and deaths; (B) costs for providing treatment, counseling, rehabilitation services; (C) costs for providing treatment of infants born with opioid-related medical conditions; (D) costs associated with law enforcement and public safety relating to the opioid epidemic, including without limitation first responders and ambulance services; and (E) any other expenses or damages caused by the Defendants' diversion of opioids;
  11. Order Defendants to fund an "abatement fund" for the purposes of abating the opioid nuisance and otherwise abate the public nuisance;
  12. Award judgment against the Defendants requiring Defendants to pay punitive and exemplary damages;
  13. Grant the Plaintiff:
    - a. Court costs, including reasonable attorney fees;
    - b. Pre-judgment and post-judgment interest, and,
    - c. All other relief as provided by law and/or as the Court deems appropriate and just.
- Plaintiffs assert claims herein in excess of the minimum jurisdictional requirements of this Court.

**PLAINTIFFS DEMAND A TRIAL BY JURY.**

Date: August 11, 2017

COUNTY OF JERSEY  
STATE'S ATTORNEY  
Benjamin L. Goetten

/s/ Ann E. Callis

Thomas J. Lech 6256261  
Ann E. Callis 6203933  
Gregory R. Jones 6325696  
Goldenberg Heller & Antognoli, P.C.  
2227 South State Route 157  
Edwardsville, IL 62025  
Tel.: 618-656-5150  
Fax: 618-656-6230  
[tlech@ghalaw.com](mailto:tlech@ghalaw.com)  
[acallis@ghalaw.com](mailto:acallis@ghalaw.com)  
[gjones@ghalaw.com](mailto:gjones@ghalaw.com)

James M. "Mike" Papantonio (*Motion to Admit pending*)  
Peter J. Mougey (*Motion to Admit pending*)  
Page A. Poerschke (*Motion to Admit pending*)  
Laura S. Dunning (*Motion to Admit pending*)  
Archie C. Lamb, Jr. (*Motion to Admit pending*)  
Jeffrey Gaddy (*Motion to Admit pending*)  
Neil E. "Ned" McWilliams, Jr. (*Motion to Admit pending*)

**Levin, Papantonio, Thomas, Mitchell,  
Rafferty & Proctor, P.A.**  
316 S. Baylen Street, Suite 600  
Pensacola, FL 32502-5996  
Tel.: 850-435-7068  
Fax: 850-436-6068  
[mpapantonio@levinlaw.com](mailto:mpapantonio@levinlaw.com)  
[pmougey@levinlaw.com](mailto:pmougey@levinlaw.com)  
[ppoerschke@levinlaw.com](mailto:ppoerschke@levinlaw.com)  
[ldunning@levinlaw.com](mailto:ldunning@levinlaw.com)  
[alambl@levinlaw.com](mailto:alambl@levinlaw.com)  
[jgaddy@levinlaw.com](mailto:jgaddy@levinlaw.com)  
[nmcwilliams@levinlaw.com](mailto:nmcwilliams@levinlaw.com)

Paul T. Farrell, Jr. (*Motion to Admit pending*)  
**Greene, Ketchum, Farrell, Bailey & Tweel, LLP**  
419 - 11th Street (25701)/ P.O. Box 2389  
Huntington, West Virginia 25724-2389  
Tel.: 800-479-0053 or 304-525-9115  
Fax: 304-529-3284  
[paul@greeneketchum.com](mailto:paul@greeneketchum.com)

Russell W. Budd  
J. Burton LeBlanc, (*Motion to Admit pending*)  
Laura J. Baughman (*Motion to Admit pending*)  
S. Ann Saucer (*Motion to Admit pending*)  
**Baron & Budd, P.C.**  
3102 Oak Lawn Avenue, Suite 1100  
Dallas, TX 75219  
Tel.: 214-521-3605  
Fax: 214-520-1181  
[rbudd@baronbudd.com](mailto:rbudd@baronbudd.com)  
[bleblanc@baronbudd.com](mailto:bleblanc@baronbudd.com)  
[lbaughman@baronbudd.com](mailto:lbaughman@baronbudd.com)  
[asaucer@baronbudd.com](mailto:asaucer@baronbudd.com)

James C. Peterson (*Motion to Admit* pending)  
R. Edison Hill (*Motion to Admit* pending)  
**Hill, Peterson, Carper,  
Bee & Deitzler, PLLC**  
NorthGate Business Park  
500 Tracy Way  
Charleston, WV 25311  
Tel.: 304-345-5667  
Fax: 304-345-1519  
[jcpeterson@hpcdb.com](mailto:jcpeterson@hpcdb.com)  
[rehill@hpcbd.com](mailto:rehill@hpcbd.com)

Roland K. Tellis (*Motion to Admit* pending)  
Mark P. Pifko (*Motion to Admit* pending)  
**Baron & Budd, P.C.**  
15910 Ventura Boulevard, Suite 1600  
Los Angeles, CA 91436  
Tel.: 818-839-2333  
Fax: 818-986-9698  
[rtellis@baronbudd.com](mailto:rtellis@baronbudd.com)  
[mpifko@baronbudd.com](mailto:mpifko@baronbudd.com)

Michael J. Fuller, Jr., (*Motion to Admit* pending)  
Amy Quezon, (*Motion to Admit* pending)  
**McHugh Fuller Law Group, PLLC**  
97 Elias Whiddon Rd.  
Hattiesburg, MS 39402  
Tel.: 601-261-2220  
Fax: 601-261-2481  
[mike@mchughfuller.com](mailto:mike@mchughfuller.com)  
[amy@mchughfuller.com](mailto:amy@mchughfuller.com)

